<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD002305" GROUP_ID="SCHIZ" ID="471600071415084940" MERGED_FROM="" MODIFIED="2013-03-12 14:19:39 +0000" MODIFIED_BY="Claire Irving" REVIEW_NO="0016" REVMAN_SUB_VERSION="5.2.3 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="10.0">
<COVER_SHEET MODIFIED="2013-03-12 14:19:39 +0000" MODIFIED_BY="Claire Irving">
<TITLE>Antidepressants for people with both schizophrenia and depression</TITLE>
<CONTACT MODIFIED="2013-03-12 14:19:39 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="8576F91C82E26AA2001DF4712A97291D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vivek</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Furtado</LAST_NAME><POSITION>Academic Clinical Fellow</POSITION><EMAIL_1>furtado.v@gmail.com</EMAIL_1><EMAIL_2>vivek.furtado@nhs.net</EMAIL_2><ADDRESS><DEPARTMENT>Forensic Psychiatry</DEPARTMENT><ORGANISATION>Rampton Hospital</ORGANISATION><ADDRESS_1>Woodbeck</ADDRESS_1><CITY>Retford</CITY><ZIP>DN22 0PD</ZIP><REGION>Nottinghamshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>07917795036</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-03-12 14:19:39 +0000" MODIFIED_BY="Claire Irving"><PERSON ID="11853A0B82E26AA201DC7B3EE2869F9F" ROLE="AUTHOR"><PREFIX>Miss</PREFIX><FIRST_NAME>Caroline</FIRST_NAME><LAST_NAME>Whitehead</LAST_NAME><POSITION>c/o Professor Glynn Lewis</POSITION><EMAIL_1>ladyc@pengwyn.freeserve.co.uk</EMAIL_1><ADDRESS><DEPARTMENT>Division of Psychiatry</DEPARTMENT><ORGANISATION>University of Bristol</ORGANISATION><ADDRESS_1>Cotham House</ADDRESS_1><ADDRESS_2>Cotham Hill</ADDRESS_2><CITY>Bristol</CITY><ZIP>BS6 6JL</ZIP><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="11851FEC82E26AA201DC7B3E46A4ED52" ROLE="AUTHOR"><PREFIX>Ms</PREFIX><FIRST_NAME>Susannah</FIRST_NAME><LAST_NAME>Moss</LAST_NAME><EMAIL_1>mosssc@cf.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Occupational Health Psychology</DEPARTMENT><ORGANISATION>Cardiff University</ORGANISATION><ADDRESS_1>63 Park Place</ADDRESS_1><ADDRESS_2>Cathays</ADDRESS_2><CITY>Cardiff</CITY><ZIP>CF10 3AS</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 2920 876399</PHONE_1><FAX_1>+44 2920 876399</FAX_1></ADDRESS></PERSON><PERSON ID="1184E38E82E26AA201DC7B3EDC652BAE" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Alastair</FIRST_NAME><LAST_NAME>Cardno</LAST_NAME><SUFFIX>MRCPsych</SUFFIX><POSITION>Senior Lecturer</POSITION><EMAIL_1>A.G.Cardno@leeds.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>Academic Unit of Psychiatry and Behavioural Sciences</DEPARTMENT><ORGANISATION>Leeds Institute of Health Sciences, University of Leeds</ORGANISATION><ADDRESS_1>Charles Thackrah Building</ADDRESS_1><ADDRESS_2>101 Clarendon Road</ADDRESS_2><CITY>Leeds</CITY><ZIP>LS2 9LJ</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 113 3432720</PHONE_1><FAX_1>+44 113 3436997</FAX_1></ADDRESS></PERSON><PERSON ID="7795" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Glyn</FIRST_NAME><LAST_NAME>Lewis</LAST_NAME><POSITION>Professor of Community and Epidemiological Psychiatry</POSITION><EMAIL_1>glyn.lewis@bristol.ac.uk</EMAIL_1><ADDRESS><DEPARTMENT>School of Social and Community Medicine</DEPARTMENT><ORGANISATION>University of Bristol</ORGANISATION><ADDRESS_1>Oakfield House</ADDRESS_1><ADDRESS_2>Oakfield Grove</ADDRESS_2><CITY>Bristol</CITY><ZIP>BS8 2BN</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 117 954 6796</PHONE_1><PHONE_2>+44 117 954 6664</PHONE_2><FAX_1>+44 117 954 6672</FAX_1></ADDRESS></PERSON><PERSON ID="8576F91C82E26AA2001DF4712A97291D" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Vivek</FIRST_NAME><MIDDLE_INITIALS>A</MIDDLE_INITIALS><LAST_NAME>Furtado</LAST_NAME><POSITION>Academic Clinical Fellow</POSITION><EMAIL_1>furtado.v@gmail.com</EMAIL_1><EMAIL_2>vivek.furtado@nhs.net</EMAIL_2><ADDRESS><DEPARTMENT>Forensic Psychiatry</DEPARTMENT><ORGANISATION>Rampton Hospital</ORGANISATION><ADDRESS_1>Woodbeck</ADDRESS_1><CITY>Retford</CITY><ZIP>DN22 0PD</ZIP><REGION>Nottinghamshire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>07917795036</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-03-12 14:08:35 +0000" MODIFIED_BY="Tessa Jane Grant">
<UP_TO_DATE>
<DATE DAY="6" MONTH="2" YEAR="2002"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="6" MONTH="2" YEAR="2002"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="12" MONTH="12" YEAR="2013"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="4" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="2" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="2" YEAR="2002"/>
</DATES>
<WHATS_NEW MODIFIED="2013-03-12 14:08:42 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-01-30 10:21:34 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="28" MONTH="1" YEAR="2013"/>
<DESCRIPTION>
<P>Update search of Cochrane Schizophrenia Group's Trial Register (see <A HREF="http://archie.cochrane.org/sections/documents/view?version=44705070754671417758120516110605&amp;format=REVMAN#SEARCH_METHODS">Search methods for identification of studies</A>), 71 studies added to awaiting classification.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-03-12 14:08:42 +0000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2013-03-12 14:08:42 +0000" MODIFIED_BY="[Empty name]">
<DATE DAY="22" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Author correction</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2008-10-22 13:23:44 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="23" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="6" MONTH="2" YEAR="2002"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Bro Taf Health Authority</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Wales College of Medicine</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>The Welsh Office</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Cochrane Schizophrenia Group General Fund</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-01-30 10:23:57 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-04-23 21:19:21 +0100" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-04-23 21:19:21 +0100" MODIFIED_BY="[Empty name]">Antidepressants for people with both schizophrenia and depression</TITLE>
<SUMMARY_BODY>
<P>Depression is common in people with schizophrenia and is associated with substantial problems including an increased risk of suicide. Many clinicians use antidepressant drugs in addition to anti-psychotics in order to treat depression. This review identified eleven randomised controlled trials that compared antidepressants with a placebo in people with schizophrenia who also had depression. There was some evidence that antidepressants did lead to an improvement in global outcome, but the small number of studies providing usable data and their poor quality, suggest that this evidence should be interpreted with caution. At present, there is no convincing evidence either to support or refute the use of antidepressants in treating depression in people with schizophrenia. Further well-designed, conducted and reported research is needed in this area.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-01-30 10:21:57 +0000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND>
<P>Depressive symptoms, often of substantial severity, are found in 50% of newly diagnosed suffers of schizophrenia and 33% of people with chronic schizophrenia who have relapsed. Depression is associated with dysphoria, disability, reduction of motivation to accomplish tasks and the activities of daily living, an increased duration of illness and more frequent relapses.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To determine the clinical effects of antidepressant medication for the treatment of depression in people who also suffer with schizophrenia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-01-30 10:21:57 +0000" MODIFIED_BY="[Empty name]">
<P>We undertook electronic searches of the Cochrane Schizophrenia Group's Register (October 2000), ClinPsych (1988-2000), The Cochrane Library (Issue 3, 2000), EMBASE (1980-2000) and MEDLINE (1966-2000). This was supplemented by citation searching, personal contact with authors and pharmaceutical companies.</P>
<P>We updated this search January 2013 and added 71 new trials to the awaiting assessment section.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised clinical trials that compared antidepressant medication with placebo for people with schizophrenia or schizoaffective disorder who were also suffering from depression.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were independently selected and extracted. For homogeneous dichotomous data the fixed effects risk difference (RD), the 95% confidence intervals (CI) and, where appropriate, the number needed to treat (NNT) were calculated on an intention-to-treat basis. For continuous data, reviewers calculated weighted mean differences. Statistical tests for heterogeneity were also undertaken.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Eleven studies met the inclusion criteria. All were small, and randomised fewer than 30 people to each group. Most included people after the most acute phase of psychosis and investigated a wide range of antidepressants. The quality of reporting varied a great deal. For the outcome of 'no important clinical response' antidepressants were significantly better than placebo (n=209, 5 RCTs, summary risk difference fixed effects -0.26, 95% CI -0.39 to -0.13, NNT 4 95% CI 3 to 8). The depression score at the end of the trial, as assessed by the Hamilton Rating Scale (HAM-D), seemed to suggest that using antidepressants was beneficial, but this was only statistically significant when a fixed effects model was used (n=261, 6 RCTs, WMD fixed effects -2.2 95% CI -3.8 to -0.6; WMD random effects -2.1 95% CI -5.04 to 0.84). There was no evidence that antidepressant treatment led to a deterioration of psychotic symptoms in the included trials. Heterogeneous data on 'any adverse effect' are equivocal (n=110, 2 RCTs, RD fixed 0.11 CI -0.03 to 0.25, Chi square 7.5, df=1, p=0.0062). In one small study extrapyramidal adverse effects were reported less often by those allocated to antidepressant (n=52, 1 RCT, RD fixed -0.28 CI -0.5 to -0.04). Only about 10% of people left these studies by 12 weeks. There was no apparent difference between those allocated placebo and those given an antidepressant (n=426, 10 RCTs, RD fixed 0.04 CI -0.02 to 0.1).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-01-30 10:21:50 +0000" MODIFIED_BY="[Empty name]">
<P>Overall, the literature was of poor quality, and only a small number of trials made useful contributions. Though our results provide some evidence to indicate that antidepressants may be beneficial for people with depression and schizophrenia, the results, at best, are likely to overestimate the treatment effect, and, at worst, could merely reflect selective reporting of statistically significant results and publication bias.</P>
<P>At present, there is no convincing evidence to support or refute the use of antidepressants in treating depression in people with schizophrenia. We need further well-designed, conducted and reported research to determine the best approach towards treating depression in people with schizophrenia.</P>
<P>Note: the 71 citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-01-30 10:23:57 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND>
<P>It is now widely recognised that depressive symptoms, often of substantial severity, are found in those whose main diagnosis is schizophrenia (<LINK REF="REF-Plasky-1991" TYPE="REFERENCE">Plasky 1991</LINK>). This 'co-morbidity' has been found to exist in 50% of newly diagnosed suffers of schizophrenia and 33% of people with chronic schizophrenia who have relapsed (<LINK REF="STD-Johnson-1981" TYPE="STUDY">Johnson 1981</LINK>). <LINK REF="REF-Martin-1985" TYPE="REFERENCE">Martin 1985</LINK>, from data collected in the large St. Louis 500 Study, suggested that 60% of people with schizophrenia also have depression.</P>
<P>Depressive symptomatology in schizophrenia is important for a number of reasons. It is associated with dysphoria and disability and reduces motivation to accomplish tasks and the activities of daily living. Depressive symptoms are associated with an increased duration of illness and more frequent relapses (<LINK REF="REF-Mulholland-2000" TYPE="REFERENCE">Mulholland 2000</LINK>). There is also evidence that the suicide risk in people with schizophrenia is associated with depressive symptoms. <LINK REF="REF-Miles-1977" TYPE="REFERENCE">Miles 1977</LINK> found that 10% of people suffering from schizophrenia committed suicide and <LINK REF="REF-Roy-1986" TYPE="REFERENCE">Roy 1986</LINK> that 57% of people with schizophrenia who commit suicide had also been depressed. Effective treatment of depressive symptomatology in schizophrenia should therefore lead to improvement in health, quality of life and reduce suicide risk. For these reasons it is common clinically to use antidepressants in addition to any antipsychotic medication. Psychological and social approaches towards the treatment of depression should also be considered but are not part of this review. </P>
<P>There are considerable problems in attempting to define depressive symptomatology in schizophrenia. Firstly there is the potential to confuse the negative symptoms of apathy, blunted affect and withdrawal, seen in schizophrenia, with depression. Secondly it is easy to confuse the extrapyramidal symptoms (EPS) and other adverse effects that occur with most conventional drug treatments for schizophrenia with depressive signs and symptoms. For example, akathisia, hypokinesia and sedation are similar to some of the symptoms of depression. 'Antimuscarinic' drugs (or anti-cholinergic drugs) can reduce EPS in those treated with antipsychotics (<LINK REF="STD-Siris-1987a" TYPE="STUDY">Siris 1987a</LINK>, <LINK REF="REF-Mulholland-2000" TYPE="REFERENCE">Mulholland 2000</LINK>). Tricyclic antidepressants, however, have 'antimuscarinic' side effects that might reduce these EPS and this can also be a problem in interpreting the results from trials. <BR/>
<BR/>For these reasons it is important to be clear about eliciting the signs and symptoms of depression within schizophrenia. As a general rule, structured assessments and clear criteria for diagnosing depression lead to more confidence in establishing depressive symptoms. Certainly, some authors have suggested that specific diagnostic criteria should be used (<LINK REF="REF-Plasky-1991" TYPE="REFERENCE">Plasky 1991</LINK>, <LINK REF="REF-Martin-1985" TYPE="REFERENCE">Martin 1985</LINK>). Optimal management of antipsychotic and anticholinergic medication is also essential before assessing depression in people with schizophrenia.</P>
<P>There is a further important aspect that has to be considered. The symptoms of depression are quite common in acute episodes of schizophrenia and, in general, these improve in parallel with the improvement in the psychosis (<LINK REF="REF-Knights-1981" TYPE="REFERENCE">Knights 1981</LINK>). <LINK REF="STD-Kramer-1989" TYPE="STUDY">Kramer 1989</LINK> suggests that tricyclic antidepressant drugs are ineffective during this acute phase of illness, and may even worsen the psychosis. On the other hand, <LINK REF="REF-Siris-1987b" TYPE="REFERENCE">Siris 1987b</LINK> suggests that, if someone is in the post-psychotic phase of treatment, an adjunctive anti-depressant might be effective, provided the psychosis is well controlled by neuroleptics. There is now some degree of clinical consensus that treatment of depressive symptoms should be after the acute psychosis has been resolved. The term post-psychotic depression has been used, though this term has been criticised for ignoring the depressive symptoms commonly found during the acute psychosis (<LINK REF="REF-Knights-1981" TYPE="REFERENCE">Knights 1981</LINK>).</P>
</BACKGROUND>
<OBJECTIVES>
<P>To determine whether antidepressant medication, as an adjunct to antipsychotic drugs, has clinically meaningful benefits for people with schizophrenia who also have clinically significant depression.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-01-28 11:57:06 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-22 13:24:47 +0100" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All relevant randomised controlled trials.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People suffering from schizophrenia, or schizoaffective disorder, diagnosed by any criteria, who had also had a depressive episode, diagnosed in any way.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. Antidepressant medication: any dose. Any antidepressant that has been licensed for use, even if subsequently withdrawn, was included.</P>
<P>There are a number of different classes of antidepressant drugs. The groupings in this review are those published in the British National Formulary (section 4.1): <BR/>· tricyclic and related drugs; <BR/>· monoamine-oxidase inhibitors (MAOI's); <BR/>· selective serotonin re-uptake inhibitors (SSRI) and related drugs; <BR/>· other antidepressant drugs.</P>
<P>It is difficult to acquire a definitive list of all antidepressants but a list is provided in order to facilitate identification of compounds.</P>
<P>Amesergide, amineptine hydrochloride, amitriptyline, amoxapine, benactyzine hydrochloride, brofaromine, bupropion hydrochloride, butriptyline hydrochloride, cianopramine, citalopram hydrobromide, clomipramine hydrochloride, clorgyline hydrochloride, clovcxamine, demexiptiline hydrochloride, desipramine hydrochloride, dibenzepin hydrochloride, dimetacrine tartrate, dothiepin hydrochloride, doxepin hydrochloride, etoperidone hydrochloride, femoxetine, fezolamine fumarate, fluoxetine hydrochloride, fluvoxamine maleate, ifoxetine, imipramine hydrochloride, iprindole hydrochloride, iproniazid phosphate, isocarboxazid, levoprotiline, lofepramine hydrochloride, maprotiline hydrochloride, medifoxamine, melitracen hydrochloride, metapramine fumarate, mianserin hydrochloride, milnacipran, minapri hydrochloride, mirtazapine, moclobemide, nefazodone hydrochloride, nialamide, nomifensine maleate, nortriptyline hydrochloride, opipramol hydrochloride, oxaflozane hydrochloride, oxaprotiline hydrochloride, oxitriptan, paroxetine hydrochloride, phenelzine sulphate, pirlindole, propizepine hydrochloride, protriptyline hydrochloride, quinupramine, rolipram, rubidium chloride, sertraline hydrochloride, setiptiline, sibutramine, teniloxazine, tianepine sodium, tofenacin hydrochloride, toloxatone, tranylcypromine sulphate, trazadone hydrochloride, trimipramine, tryptophan, venlafaxine hydrochloride, viloxazine hydrochloride, viqualine, zimelidine hydrochloride.</P>
<P>2. Placebo or active placebo (one that is known not to have antidepressant properties, but effects that mimic the adverse effects of antidepressants).</P>
<P>It was expected that everyone in the studies would also be receiving antipsychotic medication and possibly an anticholinergic.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-22 13:24:47 +0100" MODIFIED_BY="[Empty name]">
<P>The outcomes of interest were:</P>
<P>1. Death - suicide or natural causes.</P>
<P>2. Leaving the study early or drop-outs.</P>
<P>3. Clinical response:<BR/>3.1 Clinically significant response in global state - as defined by each of the studies;<BR/>3.2 Average score/change in global state;<BR/>3.3 Clinically significant response on psychotic symptoms - as defined by each of the studies;<BR/>3.4 Average score/change on psychotic symptoms;<BR/>3.5 Clinically significant response on depressive symptoms - as defined by each of the studies*;<BR/>3.6 Average score/change in depressive symptoms.*</P>
<P>4. Extrapyramidal side effects:<BR/>4.1 Use of anticholinergic drugs;<BR/>4.2 Clinically significant extrapyramidal side effects - as defined by each of the studies;<BR/>4.3 Average score/change in extrapyramidal side effects.</P>
<P>5. Other adverse effects, general and specific</P>
<P>6. Service utilisation outcomes:<BR/>6.1 Hospital admission.<BR/>6.2 Days in hospital.</P>
<P>7. Economic outcomes</P>
<P>8. Quality of life / satisfaction with care for either recipients of care or carers:<BR/>8.1. Significant change in quality of life / satisfaction - as defined by each of the studies;<BR/>8.2 Average score / change in quality of life / satisfaction.</P>
<P>All outcomes, when available, were reported for the short term (up to 12 weeks), medium term (13-26 weeks), and long term (over 26 weeks).</P>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-01-28 11:57:06 +0000" MODIFIED_BY="[Empty name]">
<P>1. Electronic searching</P>
<P>1.1. ClinPsych (SilverPlatter ASCII 3.0 DOS 1988-6/00) was searched using the phrase:</P>
<P>[(random* or ((singl* or doubl* or tripl* or trebl*) near (blind* or mask*)) or ((clin* near trial*) in ti, ab) or placebo*) and (schizo* or hebephreni* or oligophreni* or (psychotic* or psychos?s)) and (antidepressant* or tricyclic* or ssri or amesergide or amineptine or amitriptyline or amoxapine or benactyzine or brofaromine or bupropion or butriptyline or cianopramine or citalopram or clomipramine or clorgyline or clovoxamine or demexiptiline or desipramine or dibenzepin or dimetacrine or dothiepin or doxepin or etoperidone or femoxetine or fezolamine or fluoxetine or fluvoxamine or ifoxetine or imipramine or iprindole or iproniazid or isocaroxazid or levoprotiline or lofepramine or maprotiline or medifoxamine or melitracen or metapramine or mainserin or milnacipran or minapri or mirtzapine or moclobemide or nefazodone or nialamide or nomifensine or nortriptyline or opipramol or oxaflozane or oxaprotiline or oxitriptan or paroxetine or phenelzine or pirlindole or propizepine or protriptyline or quinupramine or rolipram or rubidium or sertraline or setiptiline or sibutramine or teniloxazine or tianepine or tofenacin or toloxatone or tranycypromine or trazodone or tripramine or tryptophan or venlafaxine or viloxazine or viqualine or zimeldine or depres*)]</P>
<P>1.2 Cochrane Library (Issue 3, 2000) was searched using the Cochrane Schizophrenia Group's (CSG) phrase for randomised controlled trials (see Group search strategy) combined with the phrase:</P>
<P>[exp antidepressive agents/ or exp antidepressive agents, tricyclic/ or exp amitriptyline/ or exp fluoxetine/ or exp imipramine/ or exp antidepressive agents, second-generation/ or exp serotonin antagonists/ or exp guanosine/ or exp or nortriptyline/ or exp serotonin uptake inhibitors/ or exp paroxetine/ or amesergide/ or amineptine/ or amoxapine/ or benactyzine/ or brofaromine/ or bupropion/ or butriptyline/ or cianopramine/ or citalopram/ or clomipramine/ or clorgyline/ or clovoxamine/ or demexiptiline/ or desipramine/ or dibenzepin/ or dimetacrine/ or dothiepin/ or doxepin/ or etoperidone/ or femoxetine/ or fezolamine/ or fluvoxamine/ or ifoxetine/ or iprinodole/ or iproniazid/ or isocarboxazid/ or levoprotiline/ or lofepramine/ or maprotiline/ or medifoxamine/ or melitracen/ or metapramine/ or milnacipran/ or minapri/ or mirtzapine/ or moclobemide/ or nefazodone/ or nialamide/ or nomifensine/ or nortriptyline/ or opipramol/ or oxaflozane/ or oxaprotiline/ or hydroxytryptophan/ or phenelzine/ or pirlindole/ or propizepine/ or protriptyline/ or quinupramine/ or rolipram/ or rubidium/ or sertraline/ or setiptiline/ or sibutramine/ or teniloxazine/ or tianepine/ or tofenacin/ or tranylcypromine/ or trazodone/ or tripramine/ or tryptophan/ or venlafaxine/ or viloxazine/ or viqualine/ or zimeldine/]</P>
<P>1.3 Cochrane Schizophrenia Group's Register (October 2000) was searched using the following phrase:</P>
<P>[antidepressant* or tricyclic* or ssri or amesergide or amineptine or amitriptyline or amoxapine or benactyzine or brofaromine or bupropion or butriptyline or cianopramine or citalopram or clomipramine or clorgyline or clovoxamine or demexiptiline or desipramine or dibenzepin or dimetacrine or dothiepin or doxepin or etoperidone or femoxetine or fezolamine or fluoxetine or fluvoxamine or ifoxetine or imipramine or iprindole or iproniazid or isocaroxazid or levoprotiline or lofepramine or maprotiline or medifoxamine or melitracen or metapramine or mainserin or milnacipran or minapri or mirtzapine or moclobemide or nefazodone or nialamide or nomifensine or nortriptyline or opipramol or oxaflozane or oxaprotiline or oxitriptan or paroxetine or phenelzine or pirlindole or propizepine or protriptyline or quinupramine or rolipram or rubidium or sertraline or setiptiline or sibutramine or teniloxazine or tianepine or tofenacin or toloxatone or tranycypromine or trazodone or tripramine or tryptophan or venlafaxine or viloxazine or viqualine or zimeldine or depres* or #42=476 or #42=451 or #42=23 or #42=430 or #42=67 or #42=65 or #42=16 or #42=181 or #42=236 or #42=166 or #42=433 or #42=165 or #42=512 or #42=389 or #42=410 or #42=633 or #42=608 or #42=646]</P>
<P>(#42 is the field of this Register containing intervention-specific codes).</P>
<P>1.4 EMBASE (1980 - Oct 2000) was searched using the Cochrane Schizophrenia Group's search strategy for trials relating to those with schizophrenia (see Group Module) combined with the phrase:</P>
<P>[and exp antidepressant agent/ or exp tricyclic antidepressant agent/ or exp imipramine/ or exp amitriptyline/ or depression/ or psychotropic agent/ or maio.ti,ab,hw,tn,mf. or exp serotonin uptake inhibitor/ or ssri.ti,ab,hw,tn,mf. or amineptine.ti,ab,hw,tn,mf. or amesergide.ti,ab,hw,tn,mf. or amitriptyline.ti,ab,hw,tn,mf. or amoxapine.ti,ab,hw,tn,mf. or benactyzine.ti,ab,hw,tn,mf. or brofaromine.ti,ab,hw,tn,mf. or bupropion.ti,ab,hw,tn,mf. or butriptyline.ti,ab,hw,tn,mf. or cianopramine.ti,ab,hw,tn,mf. or citalopram.ti,ab,hw,tn,mf. or clomipramine.ti,ab,hw,tn,mf. or clorgyline.ti,ab,hw,tn,mf. or clovoxamine.ti,ab,hw,tn,mf. or demexiptiline.ti,ab,hw,tn,mf. or desipramine.ti,ab,hw,tn,mf. or dibenzepin.ti,ab,hw,tn,mf. or dimetacrine.ti,ab,hw,tn,mf. or dothiepin.ti,ab,hw,tn,mf. or doxepin.ti,ab,hw,tn,mf. or etoperidone.ti,ab,hw,tn,mf. or femoxetine.ti,ab,hw,tn,mf. or fezolamine.ti,ab,hw,tn,mf. or fluoxetine.ti,ab,hw,tn,mf. or fluvoxamine.ti,ab,hw,tn,mf. or ifoxetine.ti,ab,hw,tn,mf. or imipramine.ti,ab,hw,tn,mf. or iprindole.ti,ab,hw,tn,mf. or iproniazid.ti,ab,hw,tn,mf. or isocarboxazid.ti,ab,hw,tn,mf. or levoprotiline.ti,ab,hw,tn,mf. or lofepramine.ti,ab,hw,tn,mf. or maprotiline.ti,ab,hw,tn,mf. or medifoxamine.ti,ab,hw,tn,mf. or metapramine.ti,ab,hw,tn,mf. or melitracen.ti,ab,hw,tn,mf. or mainserin.ti,ab,hw,tn,mf. or milnacipran.ti,ab,hw,tn,mf. or moclobemide.ti,ab,hw,tn,mf. or minaprine.ti,ab,hw,tn,mf. or mirtzapine.ti,ab,hw,tn,mf. or nefazodone.ti,ab,hw,tn,mf. or nialamide.ti,ab,hw,tn,mf. or nomifensine.ti,ab,hw,tn,mf. or nortriptyline.ti,ab,hw,tn,mf. or opipramol.ti,ab,hw,tn,mf. or oxaflozane.ti,ab,hw,tn,mf. or oxaprotiline.ti,ab,hw,tn,mf. or oxitriptan.ti,ab,hw,tn,mf. or -hydroxytryptophan.ti,ab,hw,tn,mf. or paroxetine.ti,ab,hw,tn,mf. or phenelzine.ti,ab,hw,tn,mf. or pirlindole.ti,ab,hw,tn,mf. or propizepine.ti,ab,hw,tn,mf. or protriptyline.ti,ab,hw,tn,mf. or quinupramine.ti,ab,hw,tn,mf. or rolipram.ti,ab,hw,tn,mf. or rubidium.ti,ab,hw,tn,mf. or sertraline.ti,ab,hw,tn,mf. or setiptiline.ti,ab,hw,tn,mf. or sibutramine.ti,ab,hw,tn,mf. or teniloxazine.ti,ab,hw,tn,mf. or tianeptine.ti,ab,hw,tn,mf. or tofenacin.ti,ab,hw,tn,mf. or toloxatone.ti,ab,hw,tn,mf. or tranylcypromine.ti,ab,hw,tn,mf. or trazadone.ti,ab,hw,tn,mf. or tripramine.ti,ab,hw,tn,mf. or tryptophan.ti,ab,hw,tn,mf. or venlafaxine.ti,ab,hw,tn,mf. or viloxazine.ti,ab,hw,tn,mf. or viqualine.ti,ab,hw,tn,mf. or zimeldine.ti,ab,hw,tn,mf.]</P>
<P>1.5 MEDLINE (January 1966 to Oct 2000) was searched using the Cochrane Schizophrenia Group's search strategy for trials relating to those with schizophrenia (see Group Module) combined with the phrase:</P>
<P>[and exp antidepressive agents/ or exp antidepressive agents, tricyclic/ or exp amitriptyline/ or exp fluoxetine/ or exp imipramine/ or exp antidepressive agents, second-generation/ or exp serotonin antagonists/ or exp guanosine/ or exp or nortriptyline/ or exp serotonin uptake inhibitors/ or exp paroxetine/ or amesergide/ or amineptine/ or amoxapine/ or benactyzine/ or brofaromine/ or bupropion/ or butriptyline/ or cianopramine/ or citalopram/ or clomipramine/ or clorgyline/ or clovoxamine/ or demexiptiline/ or desipramine/ or dibenzepin/ or dimetacrine/ or dothiepin/ or doxepin/ or etoperidone/ or femoxetine/ or fezolamine/ or fluvoxamine/ or ifoxetine/ or iprinodole/ or iproniazid/ or isocarboxazid/ or levoprotiline/ or lofepramine/ or maprotiline/ or medifoxamine/ or melitracen/ or metapramine/ or milnacipran/ or minapri/ or mirtzapine/ or moclobemide/ or nefazodone/ or nialamide/ or nomifensine/ or nortriptyline/ or opipramol/ or oxaflozane/ or oxaprotiline/ or hydroxytryptophan/ or phenelzine/ or pirlindole/ or propizepine/ or protriptyline/ or quinupramine/ or rolipram/ or rubidium/ or sertraline/ or setiptiline/ or sibutramine/ or teniloxazine/ or tianepine/ or tofenacin/ or tranylcypromine/ or trazodone/ or tripramine/ or tryptophan/ or venlafaxine/ or viloxazine/ or viqualine/ or zimeldine/]</P>
<P>(During peer review it was brought to our attention that there were some incorrectly spelt names in the lists above. We have left these as a record of the search that was undertaken. We used the catch all phrase 'antidepressant*' in the belief that this would prevent us from missing any studies. However, in the update of the review we will correct these errors)</P>
<P>1. 6 Cochrane Schizophrenia Group Trials Register<BR/>The Trials Search Co-ordinator searched the Cochrane Schizophrenia Group&#8217;s Trials Register (28 Janurary 2013)<BR/>
</P>
<P>[(*antidepress* or *triptylin* or *ameser* or *amineptin* or *amoxapin* or *benactyzin* or *brofaro* or *bupropion* or *caroxa* or *pramin* or *citalopra* or *clorgy* or *oxamine*) in title, abstract and index terms of REFERENCE) or (*antidepress* or *triptylin* or *ameser* or *amoxapin* or *ipramin* or *oxetin* or *azadon* or *amineptin* or *bupropion* or *benactyzin* or *caroxa* or *citalopram* or *clorgy* or *doxepin* or *flupent* or *fluvoxamin* or *gamfexin* or *iproniazid* or *isocarboxazid* or *maprotilin* or *mians* or *minaprin* or *mirtzapin* or *moclobemid* or *nialamid* or *nomifensin* or *pramin* or *rubidium* or *sertralin* or *tranycypromin* or *tryptophan* or *viloxazin*) in interventions of STUDY)].</P>
<P>The Cochrane Schizophrenia Group&#8217;s Trials Register is compiled by systematic searches of major databases, handsearches of relevant journals and conference proceedings (see <A HREF="http://onlinelibrary.wiley.com/o/cochrane/clabout/articles/SCHIZ/frame.html">Group Module</A>). Incoming trials are assigned to relevant existing or new review titles.</P>
<P>
<BR/>2. Citation searching</P>
<P>The citation lists from all identified studies were inspected for additional studies.</P>
<P>3. Personal contact</P>
<P>The first author of each included study published during the last ten years was contacted for additional references and for any unpublished trials.</P>
<P>4. Pharmaceutical companies</P>
<P>Companies involved in the production of the principal antidepressant drugs were contacted and requests for additional studies made.</P>
<P>5. Citations</P>
<P>All selected studies were sought as citations on the ISI database in order to identify more trials.</P>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>1. Selection of trials<BR/>The reviewers independently assessed every report identified by the electronic search for relevance to this review. In cases of disagreement, the article was obtained. Every article was then independently scrutinised by the reviewers and assessed for entry into the review. Again, in cases of disagreement this was, where possible, resolved by discussion, but if doubt remained the article was added to those awaiting assessment.</P>
<P>2. Assessment of methodological quality<BR/>The two reviewers (CW, SM) independently assigned each selected trial to quality categories described in the Cochrane Collaboration Handbook (<LINK REF="REF-Clarke-2002" TYPE="REFERENCE">Clarke 2002</LINK>). Only trials assigned to categories A and B were selected and those assigned to category C were excluded.</P>
<P>3. Data management<BR/>Two reviewers independently extracted data and resolved any disagreement by discussion (CW, SM, AC and GL). </P>
<P>4. Analysis<BR/>4.1 Intention to treat analysis <BR/>Where possible the reviewers undertook an intention-to-treat analysis with dichotomous data. The assumption was made that those who dropped out had a poor outcome. For continuous outcomes we used the data presented in the papers. If the results for continuous outcomes did not include all randomised individuals this was stated in the table of included studies.</P>
<P>4.2 Data types: Outcomes are assessed using both continuous (for example means on the Hamilton Depression rating scale; HAM-D) and dichotomous variables (for example, reduction of more than 33% in HAM-D). We used the dichotomous data provided by authors. For dichotomous outcomes, we used the risk difference as our main summary measure. </P>
<P>A wide range of rating scales is available to measure continuous outcomes in mental health trials. It was therefore decided, as a minimum standard, not to include any data from a rating scale that had not been described in a peer-reviewed journal. </P>
<P>Continuous data on outcomes in trials relevant to mental health issues are often not normally distributed. We only used data in which <BR/>(i) standard deviations and means were reported in the paper or were obtainable from the authors; and <BR/>(ii) the standard deviation (SD), was less than half the mean (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). <BR/>Although in our protocol, we stated we would only use data which met criterion (ii) in the analysis, given the scarcity of results, we decided to include that data which did not, but have indicated this in the results section. </P>
<P>For continuous mean change data (endpoint minus baseline) in the absence of individual patient data it is impossible to know if change data are skewed. The RevMan meta-analyses of continuous data are based on the assumption that the data are, at least to a reasonable degree, normally distributed or that the analyses within RevMan could cope with the unknown degree of skew. Without individual trial data it is not possible to formally check this assumption.</P>
<P>5. General<BR/>In all cases data were entered into RevMan in such a way that the area to the left of the 'line of no effect' indicates a 'favourable' outcome for the antidepressant. </P>
<P>6. Assessing the presence of publication bias <BR/>At this time there is insufficient data within the review to be able to rely upon using funnel plots or other methods to test for publication bias.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-01-30 10:23:23 +0000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-01-30 10:23:23 +0000" MODIFIED_BY="[Empty name]">
<P>1. Excluded studies<BR/>Our search method identified several hundred studies. The majority of these were rejected, as they did not meet the primary criteria. Also many studies (especially from the 1960's and 1970's) were rejected as they used the antidepressant drug for the treatment of the schizophrenia psychosis rather than for treating depression in people with schizophrenia. These studies were not included in the list of excluded studies.</P>
<P>Thirty-three studies were considered in detail and listed in the relevant table. Five were excluded, as they did not randomise the participants. Thirteen studies were excluded because the participants were not classified as depressed and one study included people without schizophrenia. Four studies did not use a placebo in the control group and nine did not use an antidepressant drug as defined. Finally, one study was excluded on the grounds that the outcome was prevention of relapse rather than treatment of the depressive syndrome itself.</P>
<P>2. Included studies</P>
<P>2.1 Participants<BR/>Recruitment occurred from both outpatient and in-patient settings. A number of the trials were quite old, and therefore the idea that the setting may help the applicability of results may be problematic. No study allocated more than 30 people to any one treatment.</P>
<P>Most studies employed the DMS-III, DSM-III-R or RDC definitions of schizophrenia. <LINK REF="STD-Johnson-1981" TYPE="STUDY">Johnson 1981</LINK>, however, used a definition of "positive Feighner or Schneiderian symptoms" that presumably corresponded to the diagnostic practices of that time in the UK. <LINK REF="STD-Kurland-1981" TYPE="STUDY">Kurland 1981</LINK> did not specify any diagnostic criteria while <LINK REF="STD-Prusoff-1979" TYPE="STUDY">Prusoff 1979</LINK> used DSM-II and the New Haven Schizophrenia Index. These latter two studies might have been using the much broader definitions of schizophrenia that were current in the USA before the widespread adoption of DSM-III. It is likely that many of these people would therefore be regarded as having affective disorders within modern classifications.</P>
<P>Eight studies used specified criteria for the diagnosis of depression. Six studies used the Hamilton Depression Scale (HAM-D; <LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>). This is a widely used rating scale that provides guidance on making ratings, but does not provide any structure for the administration of questions. A higher score indicates more depressive symptoms. Of these, three studies used a depression score of 17 or more, a common criterion used in antidepressant trials (<LINK REF="STD-Kramer-1989" TYPE="STUDY">Kramer 1989</LINK>; <LINK REF="STD-Dufresne-1988" TYPE="STUDY">Dufresne 1988</LINK>; <LINK REF="STD-Kurland-1981" TYPE="STUDY">Kurland 1981</LINK>); one study a score greater than 12 (<LINK REF="STD-Siris-1987" TYPE="STUDY">Siris 1987</LINK>); one study a score greater than 15 (<LINK REF="STD-Johnson-1981" TYPE="STUDY">Johnson 1981</LINK>) and one study only specified a score of greater than two on the depression or anergia scale of the HAM-D (<LINK REF="STD-Becker-1983" TYPE="STUDY">Becker 1983</LINK>). <LINK REF="STD-Becker-1983" TYPE="STUDY">Becker 1983</LINK> comments that 30 of the participants only scored on the anergia section of the HAM-D and not on the depression section. Two studies used the Raskin scale with a score greater than seven being required (<LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>; <LINK REF="STD-Prusoff-1979" TYPE="STUDY">Prusoff 1979</LINK>). The Research Diagnostic Criteria (<LINK REF="REF-Feighner-1972" TYPE="REFERENCE">Feighner 1972</LINK>) was used by two studies (<LINK REF="STD-Kramer-1989" TYPE="STUDY">Kramer 1989</LINK>; <LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>), and the final study simply stated that the participants were depressed (<LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK>).</P>
<P>Only three studies described the participants as being in the post-psychotic phase of illness (<LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>; <LINK REF="STD-Siris-1987" TYPE="STUDY">Siris 1987</LINK>; <LINK REF="STD-Mulholland-1997" TYPE="STUDY">Mulholland 1997</LINK>). The three studies of chronically ill people described participants as being mixed new and chronic (<LINK REF="STD-Becker-1983" TYPE="STUDY">Becker 1983</LINK>), ambulatory (<LINK REF="STD-Prusoff-1979" TYPE="STUDY">Prusoff 1979</LINK>), and one said they were in remission (<LINK REF="STD-Johnson-1981" TYPE="STUDY">Johnson 1981</LINK>). One study was with actively psychotic patients though the participants had received at least eight weeks of treatment (<LINK REF="STD-Kramer-1989" TYPE="STUDY">Kramer 1989</LINK>) and three studies did not mention the phase of illness (<LINK REF="STD-Dufresne-1988" TYPE="STUDY">Dufresne 1988</LINK>; <LINK REF="STD-Kurland-1981" TYPE="STUDY">Kurland 1981</LINK>; <LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK>) but we have classified <LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK> as stable as the participants were described as "chronic" and had been hospitalised for at least three months.</P>
<P>2.2 Interventions</P>
<P>The mean duration of washout or drug free period was two weeks although four studies did not mention a drug free period before randomisation. Two studies did not permit the use of oral anti-parkinsonian drugs (<LINK REF="STD-Kurland-1981" TYPE="STUDY">Kurland 1981</LINK>; <LINK REF="STD-Prusoff-1979" TYPE="STUDY">Prusoff 1979</LINK>). Benztropine mesylate was identified in five studies whilst the sixth study did not identify which drug was used to treat extra pyramidal symptoms.</P>
<P>The following neuroleptics were used in the studies: chlorpromazine (<LINK REF="STD-Becker-1983" TYPE="STUDY">Becker 1983</LINK>; <LINK REF="STD-Kurland-1981" TYPE="STUDY">Kurland 1981</LINK>); thiothixene (<LINK REF="STD-Becker-1983" TYPE="STUDY">Becker 1983</LINK>; <LINK REF="STD-Dufresne-1988" TYPE="STUDY">Dufresne 1988</LINK>); fluphenazine (<LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>; <LINK REF="STD-Johnson-1981" TYPE="STUDY">Johnson 1981</LINK>; <LINK REF="STD-Siris-1987" TYPE="STUDY">Siris 1987</LINK>); haloperidol (<LINK REF="STD-Kramer-1989" TYPE="STUDY">Kramer 1989</LINK>; <LINK REF="STD-Kurland-1981" TYPE="STUDY">Kurland 1981</LINK>); perphenazine (<LINK REF="STD-Prusoff-1979" TYPE="STUDY">Prusoff 1979</LINK>); and one study used several phenothiazides (<LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK>). Two studies used two different neuroleptics (<LINK REF="STD-Becker-1983" TYPE="STUDY">Becker 1983</LINK>; <LINK REF="STD-Kurland-1981" TYPE="STUDY">Kurland 1981</LINK>). The following tricyclic antidepressants were used: imipramine (<LINK REF="STD-Becker-1983" TYPE="STUDY">Becker 1983</LINK>; <LINK REF="STD-Siris-1987" TYPE="STUDY">Siris 1987</LINK>); desipramine (<LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>; <LINK REF="STD-Kramer-1989" TYPE="STUDY">Kramer 1989</LINK>); nortriptyline (<LINK REF="STD-Johnson-1981" TYPE="STUDY">Johnson 1981</LINK>); amitriptyline (<LINK REF="STD-Kramer-1989" TYPE="STUDY">Kramer 1989</LINK>; <LINK REF="STD-Prusoff-1979" TYPE="STUDY">Prusoff 1979</LINK>; <LINK REF="STD-Jasovic-1996" TYPE="STUDY">Jasovic 1996</LINK>). One study used two antidepressants (<LINK REF="STD-Kramer-1989" TYPE="STUDY">Kramer 1989</LINK>). Viloxazine (<LINK REF="STD-Kurland-1981" TYPE="STUDY">Kurland 1981</LINK>) and trazodone (<LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK>) were used in two studies and bupropion was used by <LINK REF="STD-Dufresne-1988" TYPE="STUDY">Dufresne 1988</LINK>. <LINK REF="STD-Jasovic-1996" TYPE="STUDY">Jasovic 1996</LINK> also used moclobemide and mianserin in two of the four randomised groups. Mulholland used sertraline.</P>
<P>In <LINK REF="STD-Becker-1983" TYPE="STUDY">Becker 1983</LINK>, the neuroleptic medication differed between the two randomised groups. Imipramine and chlorpromazine was therefore compared with thiothixene and placebo. In all the other studies the neuroleptic medication was the same in the two randomised groups.</P>
<P>2.3 Outcomes<BR/>Often symptom scales were used in assessing treatment effects. These scales score the presence of specific symptoms of depression and having more symptoms indicates a greater degree of depression is present.</P>
<P>2.3.1 The Brief Psychiatric Rating Scale (BPRS: <LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>)<BR/>BPRS changes in mental state were monitored by all of the trials except two (<LINK REF="STD-Johnson-1981" TYPE="STUDY">Johnson 1981</LINK>; <LINK REF="STD-Siris-1987" TYPE="STUDY">Siris 1987</LINK>). The studies gave no further details concerning the use of the BPRS.</P>
<P>2.3.2 The Clinical Global Impression (CGI) (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>)<BR/>A rating instrument commonly used in studies on schizophrenia that enables clinicians to quantify<BR/>severity of illness and overall clinical improvement during therapy. A seven-point scoring system is<BR/>usually used with low scores indicating decreased severity and/or greater recovery.</P>
<P>2.3.3 Hamilton Depression Inventory (HAM-D) (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>)<BR/>The HAM-D is a well-established 17-item scale for the measurement of depression and is sensitive to change. All of the studies except one (<LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>) used this scale.</P>
<P>The Zung Self Rating Depression Scale (<LINK REF="REF-Zung-1993" TYPE="REFERENCE">Zung 1993</LINK>), used in <LINK REF="STD-Kurland-1981" TYPE="STUDY">Kurland 1981</LINK>, the Raskin Depression Scale (<LINK REF="REF-Raskin-1970" TYPE="REFERENCE">Raskin 1970</LINK>), used in <LINK REF="STD-Prusoff-1979" TYPE="STUDY">Prusoff 1979</LINK> and the Beck Depression Inventory (<LINK REF="REF-Beck-1961" TYPE="REFERENCE">Beck 1961</LINK>), used in <LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>, all had to be excluded as adequate data were not reported.</P>
<P>Uncommon outcomes such as suicide or other deaths were not reported by any of the trials. Data on adverse effects was impossible to extract because of variability in reporting. None of the trials included quality of life measures or an economic analysis.</P>
<P>Ten of the eleven identified studies fall into the short-term category, lasting 12 weeks or less. One (<LINK REF="STD-Prusoff-1979" TYPE="STUDY">Prusoff 1979</LINK>) was classed as long term lasting 24 weeks.</P>
<P>3. Awaiting assessment</P>
<P>There are now 71 new studies waiting to be assessed from the 2013 search.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>1. Randomisation<BR/>No trial gave details about the concealment of the allocation, though three mentioned the use of computer- generated numbers. All of the studies had an even (or even + 1) number of people allocated to each group. This suggests the use of randomisation blocks. </P>
<P>2. Blinding<BR/>All studies reported using double-blind techniques, but the only details given were where two studies described using matching capsules (<LINK REF="STD-Becker-1983" TYPE="STUDY">Becker 1983</LINK>) or matching tablets (<LINK REF="STD-Kurland-1981" TYPE="STUDY">Kurland 1981</LINK>).</P>
<P>3. Loss to follow up<BR/>Three trials (<LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>; <LINK REF="STD-Johnson-1981" TYPE="STUDY">Johnson 1981</LINK>; <LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK>) did not report number of people leaving early. We assumed that there were zero dropouts from those trials. There was a particularly high dropout rate for <LINK REF="STD-Dufresne-1988" TYPE="STUDY">Dufresne 1988</LINK> and <LINK REF="STD-Prusoff-1979" TYPE="STUDY">Prusoff 1979</LINK>. The reasons for leaving the studies early were not made explicit. </P>
<P>4. Data reporting<BR/>A number of trials did not provide data on standard deviations and none provided confidence intervals for their estimates. No trials gave a priori power calculations or specified primary outcome measures. Many of the trials did not use an intention to treat strategy for the analysis. The quality of reporting was very variable, and only one of the trials has been published in a peer-reviewed journal in the last 10 years (<LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>).</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>1. The search<BR/>Thousands of citations were identified using the electronic searches. Thirty-three had to be excluded after inspection of hard copy and are described in the excluded studies table. Only eleven studies provided data that allowed inclusion.</P>
<P>2. General comments<BR/>2.1 Assumptions<BR/>Any assumptions made are stated elsewhere in the text. The main assumption was that the three trials that did not mention dropouts had zero dropouts (<LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>, <LINK REF="STD-Johnson-1981" TYPE="STUDY">Johnson 1981</LINK>, <LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK>). We further assumed that <LINK REF="STD-Kramer-1989" TYPE="STUDY">Kramer 1989</LINK> had equal groups of 22 each.</P>
<P>2.2 Overall quality<BR/>Our overall judgement of the literature, taken as a whole, was that the quality was very variable and included a number of trials that did not meet current expectations concerning the reporting of randomised controlled trials. We were also struck by the limited amount of evidence that was available. Given the variable quality of the trials and the different methods of reporting the results, the possibility of providing a quantitative synthesis is limited. </P>
<P>3. COMPARISON: ANY ANTIDEPRESSANT + ANTIPSYCHOTIC vs PLACEBO + ANTIPSYCHOTIC</P>
<P>3.1 No important clinical response<BR/>This was defined in some studies as no response in global psychiatric status, as measured by CGI, or as no significant reduction in the commonly used HAM-D scale. Such categorical data were reported by only five studies (<LINK REF="STD-Hogarty-1995" TYPE="STUDY">Hogarty 1995</LINK>; <LINK REF="STD-Johnson-1981" TYPE="STUDY">Johnson 1981</LINK>; <LINK REF="STD-Mulholland-1997" TYPE="STUDY">Mulholland 1997</LINK>; <LINK REF="STD-Prusoff-1979" TYPE="STUDY">Prusoff 1979</LINK>; <LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK>). There was a significant benefit to the use of antidepressants in the meta-analysis of these five trials (n=209, 5 RCTs, summary risk difference fixed effects -0.26, 95% CI -0.39 to -0.13, NNT 4 95% CI 3 to 8). These data were statistically homogeneous. When a random effects model was used, the results were similar (RD -0.27 95% CI -0.42 to -0.12). Only <LINK REF="STD-Johnson-1981" TYPE="STUDY">Johnson 1981</LINK> gave a criterion for recovery in terms of a reduction in HAM-D scores. All the other studies mentioned improvement on the Clinical Global Impression scale. We could not investigate publication bias using a funnel plot because of the small number of studies included in the review.</P>
<P>3.2 Mental state<BR/>3.2.1 Depressive symptoms<BR/>Six trials reported the outcome for depression assessed by the Hamilton Rating Scale (HAM-D) score at the end of the trial. Overall there seemed to be a statistically significant difference between antidepressant and placebo and benefit to using antidepressants in people with schizophrenia who are depressed. This was only apparent, however, when a fixed effects model was used (n=261, 6 RCTs, WMD fixed effects -2.2 95% CI -3.8 to -0.6; WMD random effects -2.1 95% CI -5.04 to 0.84). For three of the studies (<LINK REF="STD-Dufresne-1988" TYPE="STUDY">Dufresne 1988</LINK>; <LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK>; <LINK REF="STD-Siris-1987" TYPE="STUDY">Siris 1987</LINK>) the standard deviation was more than half the mean for at least one of the groups, indicating a severe degree of skew in the data. When the results from the trials with skewed data were separated, the remaining three trials did not find a significant benefit to the use of antidepressants, even with a fixed effects model, though of course the statistical power was reduced. In addition, there was a significant degree of heterogeneity in the results of the three trials with skewed data. In particular, the trial by <LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK> appeared to have an important influence in determining a positive result for this group of trials. <LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK> was the oldest of the trials included in the review. Finally, the continuous data used was also calculated without including all people randomised, in other words it is not clear whether the authors used an intention to treat strategy in the analysis. Of the six studies, only <LINK REF="STD-Mulholland-1997" TYPE="STUDY">Mulholland 1997</LINK>, and possibly <LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK>, used an intention to treat strategy.</P>
<P>
<LINK REF="STD-Becker-1983" TYPE="STUDY">Becker 1983</LINK> measured change using the Hamilton Scale (endpoint - baseline) but no differences were apparent (n=52, 1 RCT, MD -0.53 CI -5.6 to 4.5).</P>
<P>3.2.2 Psychotic symptoms<BR/>Some clinicians are concerned that antidepressants can lead to worsening of psychotic symptoms in schizophrenia (<LINK REF="STD-Kramer-1989" TYPE="STUDY">Kramer 1989</LINK>). We also reported from four trials on the BPRS scores at the trial endpoint. Three of these trials were studying schizophrenia during a relatively stable phase of the illness and <LINK REF="STD-Dufresne-1988" TYPE="STUDY">Dufresne 1988</LINK> did not provide information about the phase of illness. The three studies including people at the relatively stable phase of their illness found no differences between groups (n=140, 3 RCT, WMD -1.2 CI -5.2 to 2.3, heterogeneous Chi square 4.6, df 2, p=0.1). <LINK REF="STD-Dufresne-1988" TYPE="STUDY">Dufresne 1988</LINK> found a statistically significant difference favouring the placebo (n=36, 1 RCT, MD 10.6 CI 1.0 to 20).</P>
<P>Again <LINK REF="STD-Becker-1983" TYPE="STUDY">Becker 1983</LINK> measured change (endpoint - baseline) rather than end point state. Using the BPRS the study found no difference between groups (n=51, 1 RCT, MD 2.9 CI -4.0 to 10). </P>
<P>3.2.3 Adverse effects<BR/>Two studies reported on the outcome of 'any side effects'. Heterogeneous data are equivocal (n=110, 2 RCT, RD fixed 0.11 CI -0.03 to 0.25, Chi square 7.5, df=1, p=0.0062). In <LINK REF="STD-Becker-1983" TYPE="STUDY">Becker 1983</LINK> extrapyramidal adverse effects were reported less often by those allocated to antidepressant (n=52, 1 RCT, RD fixed -0.28 CI -0.5 to -0.04).</P>
<P>3.2.4 Leaving the study early<BR/>Only about 10% of people left these studies by 12 weeks. There was no difference apparent between those allocated placebo and those given an antidepressant (n=426, 10 RCT, RD fixed 0.04 CI -0.02 to 0.1). In some studies, the authors did not report any dropouts and we have assumed there were no dropouts in those studies as mentioned in the table of included studies.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>1. Limited, poor data<BR/>The literature, taken as a whole contained a number of deficiencies. Many of the studies were of poor quality from the perspective of current practice in randomised trials or did not meet the more recent criteria for reporting summarised in the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>).</P>
<P>1.1 Diagnoses<BR/>Some of the studies are now over two decades old, and may well have used diagnostic criteria for schizophrenia that do not correspond to those that have subsequently been internationally agreed. A particular danger is that these trials included people who would now receive the diagnosis of affective disorder. The diagnosis of depression can be difficult to make in people with schizophrenia. Most of the trials mentioned that they were alert to the possibility that extrapyramidal symptoms and negative symptoms of schizophrenia could mimic some aspects of the depressive syndrome. Most of the studies used the Hamilton Rating Scale for Depression to determine entry into the trial. This scale has the advantage of relying upon the clinical judgement of the clinician to decide upon the presence of symptoms. On the other hand, it is poorly standardised. A measure such as the Beck Depression Inventory, which was also used by some investigators, is a good method of determining depression in people with schizophrenia. It concentrates on some of the cognitive aspects of depression, which are therefore less likely to be confused with the extra-pyramidal symptoms and negative symptoms of schizophrenia. It is likely that the participants were heterogeneous, which supports the view that a random effects model is a more reliable method of producing a summary estimate.</P>
<P>1.2 Interventions<BR/>We chose to analyse the data for any antidepressant. It is possible, of course, that antidepressants with differing pharmacological profiles could have different effectiveness in depression in people with schizophrenia. In fact there is little evidence for different efficacy from trials of people with depression alone (<LINK REF="REF-Freemantle-2000" TYPE="REFERENCE">Freemantle 2000</LINK>). Despite this, if there were sufficient data it would be wise to check for differences in efficacy according to the pharmacological action of the antidepressant.</P>
<P>1.3 Quality of methods and reporting<BR/>All the studies were small and gave few methodological details concerning the concealment of randomisation. A number of the trials were poorly reported and gave little or no statistical information. The results were reported in a variety of ways and none gave an indication that a primary outcome had been decided before the trial began. This raises the possibility the analyses performed within the trials were selectively reported. It is unusual for so few trials (5 of 11) to have given results in terms of dichotomous outcomes. The other main quantitative analysis we were able to perform used the HAM-D as a continuous measure of outcome, but this was available in only 6 of the 11 studies. In 3 of these studies, the data appeared skewed and though one would normally expect this to increase the variance estimates, it again encourages caution in relation to the findings. There were a number of studies where the continuous outcomes may not have included all randomised subjects. This will tend to have exaggerated the treatment effect. </P>
<P>1.4 Publication bias<BR/>There is also a distinct possibility of publication bias, though we were unable to investigate this adequately. </P>
<P>2. Applicability of results<BR/>The main limitation on applying these findings to current practice may be that some of the earlier studies were not using current diagnostic criteria for schizophrenia. In particular, the studies of <LINK REF="STD-Kurland-1981" TYPE="STUDY">Kurland 1981</LINK> and <LINK REF="STD-Prusoff-1979" TYPE="STUDY">Prusoff 1979</LINK>. The study of <LINK REF="STD-Singh-1978" TYPE="STUDY">Singh 1978</LINK> used the research diagnostic criteria. One possibility is that some of the participants in these trials had affective disorders according to modern diagnostic criteria. The response to antidepressants may therefore have been overestimated.</P>
<P>It was difficult to be sure, for many studies, whether participants were in a stable post-psychotic phase of illness or whether they were still in the acute phase. We have attempted to classify the studies on the basis of the information given. For example, we have classified <LINK REF="STD-Kramer-1989" TYPE="STUDY">Kramer 1989</LINK> as stable. This was because the participants had been treated for five weeks with anti-psychotics and had shown a drop in their BPRS scores in the paper.</P>
<P>3. COMPARISON: ANY ANTIDEPRESSANT + ANTIPSYCHOTIC vs PLACEBO + ANTIPSYCHOTIC</P>
<P>3.1 Clinical response<BR/>There was a significant benefit for those allocated antidepressants (NNT 4 CI 3 to 8). However, it is important to be cautious when drawing conclusions from these data. This effect is, if anything, larger than the NNT of 7 for fluoxetine in depression (in the absence of schizophrenia) suggested by the meta-analysis of <LINK REF="REF-Bech-2000" TYPE="REFERENCE">Bech 2000</LINK>. The studies included in this outcome used a variety of different treatments and participants were recruited from several sources. </P>
<P>The evidence in this review does indicate some benefit to using antidepressants in treating depression in people with schizophrenia. The current evidence, though, is poor and a fairer conclusion is probably that the use of antidepressants is unproven. Some authors have suggested that some of the newer atypical antipsychotic drugs could be better than the more traditional antipsychotics in treating depression in people with schizophrenia (<LINK REF="STD-Tollefson-1998" TYPE="STUDY">Tollefson 1998</LINK>). This claim deserves further investigation. Nevertheless, depression is commonly found in people with schizophrenia and there will remain circumstances when clinicians will wish to treat depressive syndromes with antidepressants. The current empirical justification for this strategy is poor. Larger multicentre trials are needed if we wish to be more confident that antidepressants are effective for this clinical indication.</P>
<P>Some commentators have argued that antidepressants should not be used in the acute phase of illness and only during more stable periods. The trials did not provide clear guidance. Most of these trials, however, investigated schizophrenia after the resolution of the acute episode. Patients were often recruited from outpatient departments, or a few weeks after admission. We have much less information about whether the patients in the trials also had evidence of active psychotic phenomena in addition to any depressive symptoms, but it is likely that the participants, though stable, had psychotic symptoms in addition to any depressive symptomatology.</P>
<P>3.2 Heterogeneity<BR/>Given the heterogeneity of participants and interventions, it is unsurprising that the studies included in the continuous outcome analysis found differences in effect size. When we used a statistical model (random effects) that allowed for these differences, there was no longer any significant benefit to using antidepressant medication for depressive symptoms or general improvement. We regard the random effects model as a more conservative approach towards analysing these data and put most emphasis on this analysis. The random effects model assumes that there are different effect sizes in the different studies, and so the model estimates the distribution of effect sizes from which the individual studies have been drawn. It seems reasonable therefore to conclude that there is currently little statistical evidence to support the effectiveness of antidepressants for this clinical indication.</P>
<P>3.3 Adverse effects and leaving the study early<BR/>There was little extractable data on adverse effects. No consistent pattern emerged. More data were available on leaving the study early. This could be interpreted as a measure of the acceptability of the adjunctive treatment with antidepressants. There was not sufficient statistical evidence to suggest any difference in the number leaving the study early. This result supports the earlier conclusion that there is no evidence for any harmful effects of using antidepressants in people with schizophrenia and depression.</P>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-01-30 10:23:57 +0000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-01-30 10:23:57 +0000" MODIFIED_BY="[Empty name]">
<P>1. For clinicians<BR/>The evidence summarised in this review is not sufficiently robust to provide clear guidance about the use of antidepressants to treat depression in schizophrenia. Neither does it refute the use of antidepressants for those whose psychotic schizophrenic illness is complicated by clear depressive syndrome. On balance it supports the use of antidepressants for this indication but the treatment effect calculated by the meta-analysis is probably an overestimate and the statistical results only suggest benefit in some of the analyses. There was no evidence to support a harmful effect of antidepressants once the acute phase of illness was over.</P>
<P>2. For people with schizophrenia<BR/>People with schizophrenia with additional symptoms of depression can be reassured that there are no data to refute the use, and some to support adding antidepressants to standard antipsychotic regimens. It would be entirely understandable, however, if people offered adjunctive medication were only to accept it within the context of a well-designed randomised trial.</P>
<P>3. For policy makers<BR/>Currently there is no good information to guide policy makers.</P>
<P>4. Note: the 71 new citations in the awaiting classification section of the review may alter the conclusions of the review once assessed.<BR/>
</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>1. General<BR/>Even with these few studies, data were lost because of poor reporting. We would all be better informed if all data were either reported in usable form or were at least accessible from authors or a central repository.</P>
<P>2. Specific<BR/>At present there is no convincing evidence to support the use of antidepressants in the treatment of depression in people with schizophrenia. Depression in schizophrenia is an important and common clinical problem. Determining the optimal pharmacological method of treating depression in this group will require further research. Further research is needed in order to guide clinicians in their management and use of antidepressant medication. This review, if nothing else, should help guide researchers to design a study of adequate power (at least 150 per group) and the use of clinically meaningful outcomes.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>This review was made possible thanks to the Clinical Effectiveness Support Unit of the Welsh Office. The reviewers would also like to thank Clive Adams and Leanne Roberts for all their help and advice during the production of this review. We also acknowledge the help and advice of Hollie Thomas. Letters were sent to all of the main authors and we are grateful to those who responded: Professor E. Hogarty, Dr R Dufresne, Professor M Jasovic Gasic and Ciaran Mulholland.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Glyn Lewis - had the original idea for the review, devised the protocol, and reviewed papers, extracted data and contributed to the final version of the review. </P>
<P>Caroline Whitehead - had the original idea for the review, devised the protocol, performed the literature searches, the initial screening of the studies, reviewed papers, extracted data and contributed to the final version of the review.</P>
<P>Su Moss - had the original idea for the review, devised the protocol, and reviewed papers, extracted data and contributed to the final version of the review.</P>
<P>Alastair Cardno - contributed to the final version of the review.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-03-12 14:13:00 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-01-30 10:13:00 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2009-02-02 12:20:55 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Becker-1983" NAME="Becker 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Becker RE</AU>
<TI>Implications of the efficacy of thiothixene and chlorpormazine-imipramine combination for depression in schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1983</YR>
<VL>140</VL>
<NO>2</NO>
<PG>208-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dufresne-1988" NAME="Dufresne 1988" YEAR="1988">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Dufresne RL, Kass DJ, Becker RE</AU>
<TI>Bupropion and thiothixene versus placebo and thiothixine in the treatment of depression in schizophrenia</TI>
<SO>Drug Development Research</SO>
<YR>1988</YR>
<VL>12</VL>
<PG>256-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hogarty-1995" NAME="Hogarty 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogarty GE, McEvoy JP, Ulrich RF, DiBarry AL, Bartone P, Cooley S, Hammill K, Carter M, Munetz MR, Perel J</AU>
<TI>Pharmacotherapy of impaired affect in recovering schizophrenic patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1995</YR>
<VL>52</VL>
<PG>29-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jasovic-1996" NAME="Jasovic 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Jasovic-Gasic M, Nikolic-Balkoski G, Kunovac J, Kuzmanovic V, Crnobaric C, Krsmanovic M</AU>
<TI>Antidepressants in the Treatment of Depressive Syndrome in Schizophrenia</TI>
<SO>XXth Collegium Internationale Neuro-psychopharmacologicum</SO>
<YR>1966</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-1981" MODIFIED="2009-02-02 12:20:55 +0000" MODIFIED_BY="[Empty name]" NAME="Johnson 1981" YEAR="1981">
<REFERENCE MODIFIED="2009-02-02 12:20:55 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Johnson DAW</AU>
<TI>A double blind trial of Nortriptyline for depression in chronic schizophrenia</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1981</YR>
<VL>139</VL>
<PG>89-101</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kramer-1989" NAME="Kramer 1989" YEAR="1989">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kramer MS, Vogel WH, DiJohnson C, Dewey DA, Sheves P, Cavicchia S, Little P, Schmidt R, Kimes I</AU>
<TI>Antidepressants in 'depressed' schizophrenic inpatients. A controlled trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1989</YR>
<VL>46</VL>
<PG>922-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kurland-1981" NAME="Kurland 1981" YEAR="1981">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kurland A, Nagaraju A</AU>
<TI>Viloxazine and the depressed schizophrenic - methodological issues</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1981</YR>
<VL>21</VL>
<PG>37-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Mulholland-1997" NAME="Mulholland 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mulholland C, Lynch G, Cooper SJ, King DJ</AU>
<TI>A double-blind, placebo-controlled trial of sertraline for depressive symptoms in stable, chronic schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>42</VL>
<PG>188S-9S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prusoff-1979" NAME="Prusoff 1979" YEAR="1979">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Prusoff BA, Williams DH, Weissman MM, Astrachan BM</AU>
<TI>Treatment of secondary depression in schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1979</YR>
<VL>36</VL>
<PG>569-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Singh-1978" NAME="Singh 1978" YEAR="1978">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Singh AN, Saxena B, Nelson HL</AU>
<TI>A controlled clinical study of trazondone in chronic schizophrenic patients with pronounced depressive symptomatology</TI>
<SO>Current Therapeutic Research</SO>
<YR>1978</YR>
<VL>23</VL>
<PG>485-501</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1987" NAME="Siris 1987" YEAR="1987">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Morgan V, Fagerstrom R, Rifkin A, Cooper TB</AU>
<TI>Adjunctive imipramine in the treatment of postpsychotic depression. A controlled trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1987</YR>
<VL>44</VL>
<PG>533-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2013-01-30 10:13:00 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Arango-2000" NAME="Arango 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Arango C, Kirkpatrick B, Buchanan R</AU>
<TI>Fluoxetine as an adjunct to conventional antipsychotic treatment of schizophrenia patients with residual symptoms</TI>
<SO>Journal of Mental and Nervous Disease</SO>
<YR>2000</YR>
<VL>188</VL>
<NO>1</NO>
<PG>50-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Arato-1998" NAME="Arato 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Arato M, O'Connor R, Bradbury JE, Meltzer H</AU>
<TO>The efficacy of ziprasidone in the long term treatment of negative symptoms and prevention of exacerbation of schizophrenia</TO>
<SO>XXIst CINP Congress, Glasgow, Scotland</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Benkert-1996" NAME="Benkert 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Benkert O, Muller-Siecheneder F, Wetzel H</AU>
<TO>Negative and depressed symptoms in acute schizophrenic episodes - do they improve under neuroleptic treatment?</TO>
<SO>8th Congress of the Association of European Psychiatrists, 1996, London</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Duval-1997" NAME="Duval 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Duval F, Mokrani MC, Crocq M-A, Bailey P, Diep TS, Correa H</AU>
<TO>DST status and dopamine function in psychotic depression</TO>
<SO>150th Annual Meeting, American Psychiatric Association</SO>
<YR>1997</YR>
<CY>San Diego.</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eikmeier-1991" NAME="Eikmeier 1991" YEAR="1991">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Ekmeier G, Berger M, Lodemann E,</AU>
<TI>Trimipramine - and atypical antipsychotic?</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1991</YR>
<VL>6</VL>
<PG>147-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goff-1990" NAME="Goff 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Brotman AW, Waites M, McCormick S</AU>
<TI>Trial of fluoxetine added to neuroleptics for treatment-resistant schizophrenic patients</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>147</VL>
<PG>492-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goff-1995" NAME="Goff 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Goff DC, Midha KK, Sarid SO, Hubbard JW, Amico E</AU>
<TI>A placebo-controlled trial of fluoxetine added to neuroleptic in patients with schizophrenia</TI>
<SO>Psychopharmacology</SO>
<YR>1995</YR>
<VL>117</VL>
<PG>417-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Goode-1983" NAME="Goode 1983" YEAR="1983">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Goode DJ, Manning AA</AU>
<TI>Comparison of Bupropion alone and with haloperidol in schizo-affective disorder, depressed type</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1983</YR>
<VL>44</VL>
<NO>7</NO>
<PG>253-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hiemke-1994" NAME="Hiemke 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hiemke C, Weigmann H, Hartter S, Dahmen N, Wetzel H, Muller H</AU>
<TI>Elevated levels of clozapine in serum after addition of fluvoxamine</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>14</VL>
<PG>279-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Joffe-1998" NAME="Joffe 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Joffe G, Rimon R</AU>
<TI>Adjunctive nefazodone in neuroleptic-treated schizophrenic patients with depressive and negative symptoms - A preliminary report</TI>
<SO>Nordic Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>52</VL>
<NO>Suppl 41</NO>
<PG>168-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kirli-1998" NAME="Kirli 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kirli S, Caliskan M</AU>
<TI>A comparitive study of sertraline versus imipramine in postpsychotic depressive disorder of schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>33</VL>
<PG>103-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knights-1979" NAME="Knights 1979" YEAR="1979">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knights A, Okasha M, Salih M, Hirsch SR</AU>
<TI>Depressive and extrapyramidal symptoms and clinical effects: a trial of fluphenazine versus flupenthixol in maintenance of schizophrenic out-patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1979</YR>
<VL>135</VL>
<PG>515-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Koreen-1993" NAME="Koreen 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Koreen AR, Siris SG, Chakos M, Mayerhoff D, Lieberman J</AU>
<TI>Depression in first-episode schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1993</YR>
<VL>150</VL>
<NO>11</NO>
<PG>1643-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krakowski-1997" NAME="Krakowski 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Krakowski M, Czobor P, Volavka J</AU>
<TI>Effect of neuroleptic treatment on depressive symptoms in acute schizophrenic episodes</TI>
<SO>Psychiatry Research</SO>
<YR>1997</YR>
<VL>71</VL>
<NO>1</NO>
<PG>19-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1996" NAME="Lee 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Lee MS, Kim SH, Han CS</AU>
<TI>Co-administration of Paroxetine and Haloperidol in chronic schizophrenia</TI>
<SO>XXth Collegium Internationale Neuro-psychopharmacologicum, 1996</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-1998" MODIFIED="2013-01-30 10:13:00 +0000" MODIFIED_BY="[Empty name]" NAME="Lee 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-01-30 10:13:00 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee MS, Kim YK, Lee SK, Suh KY</AU>
<TI>A double blind study of adjunctive sertraline in haloperidol-stabilized patients with chronic schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>5</NO>
<PG>399-403</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-1998" NAME="Muller 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller-Siecheneder F, Muller MJ, Hillert A, Wetzel H, Benkert O</AU>
<TI>Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>2</NO>
<PG>111-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salokangas-1996" NAME="Salokangas 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Salokangas RKR, SaarijarviS, Taiminen T, Kallioniemi H, Lehto H, Niemi H, Tuominen J, Aloha V, Syvalahti E</AU>
<TI>Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1996</YR>
<VL>94</VL>
<PG>175-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Taiminen TJ, Syvalahti, E, Saarijarvi, S Niemi H, Lehto H, Aloha V, Salonkangas, RKR</AU>
<TI>Citalopram and an adjunct in schizophrenia: further evidence for a serotinergic dimension in schizophrenia</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>12</VL>
<PG>31-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silver-1992" NAME="Silver 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silver H, Nassar A</AU>
<TI>Fluvoxamine improves negative symptoms in treated chronic schizophrenia: an add on double blind, placebo controlled study</TI>
<SO>Biological Psychiatry</SO>
<YR>1992</YR>
<VL>31</VL>
<PG>698-704</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silver-1998" NAME="Silver 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silver H, Shmugliakov N</AU>
<TI>Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia: evidence for a specific serotonergic effect from a double-blind study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1998</YR>
<VL>18</VL>
<NO>3</NO>
<PG>208-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1982" NAME="Siris 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Cooper TB, Rifkin AE, Brenner R, Lieberman JA</AU>
<TI>Plasma imipramine concentrations in patients receiving concomitant fluphenazine decanoate</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1982</YR>
<VL>139</VL>
<PG>104-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1986" NAME="Siris 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Rifkin A, Reardon GT, Doddi SR, Strahan A, Hall KS</AU>
<TI>Stability of the Postpsychotic depression syndrome</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1986</YR>
<VL>47</VL>
<PG>86-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1987a" NAME="Siris 1987a" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Adan F, Cohen M, Mandeli J, Aronson A, Fasano Dube B</AU>
<TI>Targeted treatment of depression-like symptoms in schizophrenia</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1987</YR>
<VL>23</VL>
<PG>85-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1989" NAME="Siris 1989" YEAR="1989">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Cutler J, Owen K, Mason SE, Gingerich S, Lang MP</AU>
<TI>Adjunctive imipramine maintenance treatment in schizophrenic patients with remitted postpsychotic depression</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1989</YR>
<VL>146</VL>
<PG>1495-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Strahan A</AU>
<TI>Continuation and maintenance of adjunctive imipramine therapy in patients with post psychotic depression</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1988</YR>
<VL>49</VL>
<NO>11</NO>
<PG>439-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1990" NAME="Siris 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Mason SE, Bermanzohn PC, Alvir JM, McCorry TA</AU>
<TI>Adjunctive imipramine maintenance in post-psychotic depression/negative symptoms</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1990</YR>
<VL>26</VL>
<NO>1</NO>
<PG>91-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1993" NAME="Siris 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Mason SE, Bermanzohn PC, Shuwall MA, Aseniero MA</AU>
<TI>Adjunctive imiprimine in substance abusing dysphoric schizophrenic patients</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1993</YR>
<VL>29</VL>
<PG>127-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Siris-1994" NAME="Siris 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG, Bermanzohn PC, Mason SE, Shuwall MA</AU>
<TI>Maintenance imipramine therapy for secondary depression in schizophrenia: A controlled trial</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1994</YR>
<VL>51</VL>
<PG>109-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Spina-1994" NAME="Spina 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Spina E, De Domenico P, Ruello C, Longobardo N, Gitto C, Ancione M, Di Rosa AE, Caputi AP</AU>
<TI>Adjunctive fluoxetine in the treatment of negative symptoms in chronic schizophrenic patients.</TI>
<SO>International Clinical Psychopharmacology</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>281-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thakore-1996" NAME="Thakore 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thakore JH, Berti C, Dinan TG</AU>
<TI>An open trial of adjunct sertraline in the treatment of chronic schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1996</YR>
<VL>94</VL>
<PG>194-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollefson-1996" NAME="Tollefson 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson G, Lu Y</AU>
<TO>Comorbid mood disturbance in schizophrenia</TO>
<SO>9th ECNP (European College of Neuropsychopharmacology) Congress, 1996 Sept 21-25th, Amsterdam, The Netherlands</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Tollefson G, Lu Y</AU>
<TI>Comorbid mood disturbance in schizophrenia</TI>
<SO>XXth Collegium Internationale Neuro-psychopharmacologicum, 1996</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollefson-1998" NAME="Tollefson 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Sanger TM, Lu Y, Thieme ME</AU>
<TI>Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1998</YR>
<VL>55</VL>
<NO>3</NO>
<PG>250-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tollefson-1999" NAME="Tollefson 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tollefson GD, Sanger TM</AU>
<TI>Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacology?</TI>
<SO>Schizophrenia Research</SO>
<YR>1999</YR>
<VL>35</VL>
<NO>Suppl</NO>
<PG>13-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Waehrens-1980" NAME="Waehrens 1980" YEAR="1980">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Waehrens J, Gerlach J</AU>
<TI>Antidepressant drugs in anergic schizophrenia: a double-blind cross-over study with maprotiline and placebo</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1980</YR>
<VL>61</VL>
<PG>438-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2013-01-30 10:11:23 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Addington-2002" MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" NAME="Addington 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Addington D, Addington J, Patten S, Remington G, Moamai J, Labelle A, et al</AU>
<TI>Double-blind, placebo-controlled comparison of the efficacy of sertraline as treatment for a major depressive episode in patients with remitted schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>1</NO>
<PG>20-5</PG>
<IDENTIFIERS MODIFIED="2013-01-29 16:46:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="11799338"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Addington-2002a" MODIFIED="2013-01-30 09:52:01 +0000" MODIFIED_BY="[Empty name]" NAME="Addington 2002a" YEAR="2002">
<REFERENCE MODIFIED="2013-01-30 09:52:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Addington DE, Addington JM, Patten SB, Remington GJ, Moamai J, Labelle A, et al</AU>
<TI>Sertraline for depression in remitted schizophrenia</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2013-01-30 09:52:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Berk-2002" MODIFIED="2013-01-30 09:52:18 +0000" MODIFIED_BY="[Empty name]" NAME="Berk 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-30 09:52:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Berk M, Ichim C, Brook S</AU>
<TI>Mirtazepine treatment of negative schizophrenia</TI>
<SO>Proceedings of the 155th Annual Meeting of the American Psychiatric Association; 2002 May 18-23; Philadelphia, Pennsylvania, USA</SO>
<YR>2002</YR>
<IDENTIFIERS MODIFIED="2013-01-30 09:52:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Blumberger-2011" MODIFIED="2013-01-30 09:52:28 +0000" MODIFIED_BY="[Empty name]" NAME="Blumberger 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-30 09:52:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blumberger DM, Mulsant BH, Emeremni C, Houck P, Andreescu C, Mazumdar S, et al</AU>
<TI>Impact of prior pharmacotherapy on remission of psychotic depression in a randomized controlled trial</TI>
<SO>Journal of Psychiatric Research</SO>
<YR>2011</YR>
<VL>45</VL>
<NO>7</NO>
<PG>896-901</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:52:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chen-2007" MODIFIED="2013-01-30 09:52:39 +0000" MODIFIED_BY="[Empty name]" NAME="Chen 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-30 09:52:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chen K</AU>
<TI>Fluoxetine in the treatment of schizophrenic depression</TI>
<TO>&#27679;&#35199;&#27712;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;&#30340;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2007</YR>
<VL>19</VL>
<NO>11</NO>
<PG>486, 488</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:52:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dawes-2012" MODIFIED="2013-01-30 09:52:50 +0000" MODIFIED_BY="[Empty name]" NAME="Dawes 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-01-30 09:52:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dawes SE, Palmer BW, Meeks T, Golshan S, Kasckow J, Mohamed S, et al</AU>
<TI>Does antidepressant treatment improve cognition in older people with schizophrenia or schizoaffective disorder and comorbid subsyndromal depression?</TI>
<SO>Neuropsychobiology</SO>
<YR>2012</YR>
<VL>65</VL>
<NO>3</NO>
<PG>168-72</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:52:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Eli-2006" MODIFIED="2013-01-30 09:53:03 +0000" MODIFIED_BY="[Empty name]" NAME="Eli 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-30 09:53:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Eli LandC</AU>
<TI>Fluoxetine augmentation in schizophrenic or schizoaffective patients with depressive or negative symptoms who are partial or nonresponders to olanzapine</TI>
<SO>http://www.clinicalstudyresults.org/</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2013-01-30 09:53:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fitzgerald-2004" MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" NAME="Fitzgerald 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fitzgerald PB, Filia S, De Castella A, McBain N, Kapur S, Kulkarni J</AU>
<TI>Amoxapine in schizophrenia: a negative double-blind controlled trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>4</NO>
<PG>448-50</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2013-01-29 16:46:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15232339"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Friedman-2005" MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" NAME="Friedman 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Friedman JI, Ocampo R, Elbaz Z, Parrella M, White L, Bowler S, et al</AU>
<TI>The effect of citalopram adjunctive treatment added to atypical antipsychotic medications for cognitive performance in patients with schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>3</NO>
<PG>237-42</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2013-01-29 16:46:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="15876902"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Geddes-2010" MODIFIED="2013-01-30 09:53:15 +0000" MODIFIED_BY="[Empty name]" NAME="Geddes 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-30 09:53:15 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Geddes J</AU>
<TI>Mirtazapine for schizophrenia</TI>
<SO>Stanley Foundation Research Programs</SO>
<YR>2010</YR>
<IDENTIFIERS MODIFIED="2013-01-30 09:53:15 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gerson-1970" MODIFIED="2013-01-30 09:54:38 +0000" MODIFIED_BY="[Empty name]" NAME="Gerson 1970" YEAR="1970">
<REFERENCE MODIFIED="2013-01-30 09:54:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gerson F</AU>
<TI>Ketipramine versus imipramine</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1970</YR>
<VL>7</VL>
<NO>2</NO>
<PG>49-52</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:54:38 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gunby-1966" MODIFIED="2013-01-30 09:54:54 +0000" MODIFIED_BY="[Empty name]" NAME="Gunby 1966" YEAR="1966">
<REFERENCE MODIFIED="2013-01-30 09:54:54 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gunby B, Steenfeldt-Foss OW</AU>
<TI>Triperidol, a new psychopharmacon in the treatment of psychoses</TI>
<SO>Tidsskrift for Den Norske Laegeforening</SO>
<YR>1966</YR>
<VL>14</VL>
<PG>1048-51</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:54:45 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Han-2006" MODIFIED="2013-01-30 09:54:59 +0000" MODIFIED_BY="[Empty name]" NAME="Han 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-30 09:54:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Han Z-F, Zhou S-B, Sun X-D</AU>
<TI>Controlled study of cognitive behavior therapy in treatment of schizophrenia with depressive symptoms</TI>
<TO>&#35748;&#30693;&#34892;&#20026;&#30103;&#27861;&#23545;&#31934;&#31070;&#20998;&#35010;&#30151;&#20276;&#21457;&#25233;&#37057;&#38556;&#30861;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Medical Journal of Chinese People's Health [&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;]</SO>
<YR>2006</YR>
<VL>18</VL>
<NO>3</NO>
<PG>176-8</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:54:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hu-2004" MODIFIED="2013-01-30 09:55:09 +0000" MODIFIED_BY="[Empty name]" NAME="Hu 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-30 09:55:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hu P, Xu T</AU>
<TI>The clinical effects contrast of cognitive therapy and amitriptyline on patients with post - schizophrenia depression</TI>
<SO>Chinese Medical Journal of Metallurgical Industry [&#20013;&#22269;&#20918;&#37329;&#24037;&#19994;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2004</YR>
<VL>21</VL>
<NO>3</NO>
<PG>186-7</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:55:09 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2003" MODIFIED="2013-01-30 09:55:14 +0000" MODIFIED_BY="[Empty name]" NAME="Huang 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-30 09:55:14 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang Y, Jiang N, Zhang X</AU>
<TI>A clinical study of flouxetine to treat depressive symptoms of schizophrenia patients</TI>
<SO>Health Psychology Journal</SO>
<YR>2003</YR>
<VL>7476</VL>
<NO>3</NO>
<PG>239-40</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:55:14 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-ISRCTN42305247-2010" MODIFIED="2013-01-30 09:55:20 +0000" MODIFIED_BY="[Empty name]" NAME="ISRCTN42305247 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-30 09:55:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Barnes T</AU>
<TI>Antidepressant controlled trial for negative symptoms in schizophrenia (ACTIONS)</TI>
<SO>National Institute for Health Research</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2013-01-30 09:55:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-30 09:44:53 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>ISRCTN42305247</AU>
<TI>Antidepressant controlled trial for negative symptoms in schizophrenia</TI>
<SO>http://www.controlled-trials.com</SO>
<YR>2010</YR>
<IDENTIFIERS MODIFIED="2013-01-30 09:44:53 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Izakova-2007" MODIFIED="2013-01-30 09:55:29 +0000" MODIFIED_BY="[Empty name]" NAME="Izakova 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-30 09:55:29 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Izakova L</AU>
<TI>Monotherapy and combination therapy of schizoaffective disorder, depressive type</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>Suppl 4</NO>
<PG>S414</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:55:29 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Izakova-2009" MODIFIED="2013-01-30 09:57:01 +0000" MODIFIED_BY="[Empty name]" NAME="Izakova 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-30 09:57:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Izakova L, Andre I, Halaris A</AU>
<TI>Combination therapy or monotherapy for the depressed type of schizoaffective disorder</TI>
<SO>Neuropsychiatric Disease and Treatment</SO>
<YR>2009</YR>
<VL>5</VL>
<NO>1</NO>
<PG>91-101</PG>
<CY>New Zealand</CY>
<IDENTIFIERS MODIFIED="2013-01-30 09:57:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jasovic_x002d_Gasic-1990" MODIFIED="2013-01-30 09:57:10 +0000" MODIFIED_BY="[Empty name]" NAME="Jasovic-Gasic 1990" YEAR="1990">
<REFERENCE MODIFIED="2013-01-30 09:57:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Jasovic-Gasic M, Kunovac J, Banic Z, Paunovic VR</AU>
<TI>Depression in schizophrenia: psychopharmacological possibilities</TI>
<SO>Proceedings of the 17th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1990 Sep 10-14; Kyoto, Japan</SO>
<YR>1990</YR>
<PG>263</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:57:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jasovic_x002d_Gasic-1991" MODIFIED="2013-01-30 09:57:20 +0000" MODIFIED_BY="[Empty name]" NAME="Jasovic-Gasic 1991" YEAR="1991">
<REFERENCE MODIFIED="2013-01-30 09:57:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jasovic-Gasic M, Danic Z, Kunovac J</AU>
<TI>Efficacy of mianserni and amitriptyline in the treatment of depression in schizophrenia: comparative study</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1991</YR>
<VL>15</VL>
<NO>Suppl 1 Pt B</NO>
<PG>249B</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:57:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jin-2002" MODIFIED="2013-01-30 09:57:26 +0000" MODIFIED_BY="[Empty name]" NAME="Jin 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-30 09:57:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jin Z, Chen W, Yuan B</AU>
<TI>A clinical observation of treatment of negative symptoms in schizophrenia with a combination of fluoxetine and clozapine</TI>
<SO>Journal of Clinical Psychological Medicine [&#20020;&#24202;&#31934;&#31070;&#21307;&#23398;&#26434;&#24535;]</SO>
<YR>2002</YR>
<VL>12</VL>
<NO>2</NO>
<PG>76-7</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:57:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasckow-2001" MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" NAME="Kasckow 2001" YEAR="2001">
<REFERENCE MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasckow JW, Mohamed S, Thallasinos A, Carroll B, Zisook S, Jeste DV</AU>
<TI>Citalopram augmentation of antipsychotic treatment in older schizophrenia patients</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2001</YR>
<VL>16</VL>
<PG>1163-7</PG>
<EN>12</EN>
<CY>UK</CY>
<IDENTIFIERS MODIFIED="2013-01-29 16:46:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="11748776"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kasckow-2010a" MODIFIED="2013-01-30 09:57:38 +0000" MODIFIED_BY="[Empty name]" NAME="Kasckow 2010a" YEAR="2010">
<REFERENCE MODIFIED="2013-01-30 09:57:38 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasckow J, Fellows I, Golshan S, Solorzano E, Meeks T, Zisook S</AU>
<TI>Treatment of subsyndromal depressive symptoms in middle-age and older patients with schizophrenia: Effect of age on response</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2010</YR>
<VL>18</VL>
<NO>9</NO>
<PG>853-7</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:57:38 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kim-2006" MODIFIED="2013-01-30 09:57:44 +0000" MODIFIED_BY="[Empty name]" NAME="Kim 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-30 09:57:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Kim H, Lee KJ, Lee SH</AU>
<TI>Citalopram for depressive symptoms in chronic schizophrenia</TI>
<SO>Proceedings of the 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto, Canada</SO>
<YR>2006</YR>
<IDENTIFIERS MODIFIED="2013-01-30 09:57:44 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Krumholz-1968" MODIFIED="2013-01-30 09:57:52 +0000" MODIFIED_BY="[Empty name]" NAME="Krumholz 1968" YEAR="1968">
<REFERENCE MODIFIED="2013-01-30 09:57:52 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krumholz</AU>
<TI>MO-1255 versus Imipramine</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1968</YR>
<VL>5</VL>
<NO>2</NO>
<PG>49-51</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:57:52 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lehmann-1970" MODIFIED="2013-01-30 09:57:59 +0000" MODIFIED_BY="[Empty name]" NAME="Lehmann 1970" YEAR="1970">
<REFERENCE MODIFIED="2013-01-30 09:57:59 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lehmann HE, Ban TA</AU>
<TI>Doxepin in schizophrenics</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1970</YR>
<VL>7</VL>
<NO>2</NO>
<PG>55-7</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:57:59 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2002" MODIFIED="2013-01-30 09:58:04 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-30 09:58:04 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y, Xu M, Zheng S</AU>
<TI>A clinical control study of venlafaxine and clomipramine in the treatment of post-schizophrenic depression</TI>
<TO>&#19975;&#25289;&#27861;&#26032;&#19982;&#27695;&#19993;&#21674;&#21994;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2002</YR>
<VL>15</VL>
<NO>4</NO>
<PG>216-8</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:58:04 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Liu-2003" MODIFIED="2013-01-30 09:58:10 +0000" MODIFIED_BY="[Empty name]" NAME="Liu 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-30 09:58:10 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Liu Y, Feng W, Xu M</AU>
<TI>A comparative study of vanlafaxine and fluoxetine in the treatment of post-schizophrenic depression</TI>
<SO>Medical Journal of Chinese Civil Administration</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>6</NO>
<PG>327-9</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:58:10 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulholland-1997a" MODIFIED="2013-01-30 09:58:26 +0000" MODIFIED_BY="[Empty name]" NAME="Mulholland 1997a" YEAR="1997">
<REFERENCE MODIFIED="2013-01-30 09:58:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mulholland C, Lynch G, Cooper SJ, King DJ</AU>
<TI>A double-blind, placebo-controlled trial of sertraline for depressive symptoms in stable, chronic schizophrenia</TI>
<SO>Biological Psychiatry</SO>
<YR>1997</YR>
<VL>42</VL>
<PG>188S-9S</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:58:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulholland-1998" MODIFIED="2013-01-30 09:58:32 +0000" MODIFIED_BY="[Empty name]" NAME="Mulholland 1998" YEAR="1998">
<REFERENCE MODIFIED="2013-01-30 09:58:32 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mulholland C, Lynch G, King DJ, Cooper SJ</AU>
<TI>A randomised controlled trial of sertraline for depressive symptoms in stable, chronic schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>1</NO>
<PG>153-4</PG>
<IDENTIFIERS MODIFIED="2013-01-30 09:58:32 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mulholland-2003" MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" NAME="Mulholland 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mulholland C, Lynch G, King DJ, Cooper SJ</AU>
<TI>A double-blind, placebo-controlled trial of sertraline for depressive symptoms in patients with stable, chronic schizophrenia</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2003</YR>
<VL>17</VL>
<NO>1</NO>
<PG>107-12</PG>
<CY>United Kingdom</CY>
<IDENTIFIERS MODIFIED="2013-01-29 16:46:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="12680747"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Muller-1997" MODIFIED="2013-01-30 10:00:34 +0000" MODIFIED_BY="[Empty name]" NAME="Muller 1997" YEAR="1997">
<REFERENCE MODIFIED="2013-01-30 10:00:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Muller MJ, Benkert O</AU>
<TI>Depressive symptoms in acute schizophrenia: evaluation and outcome under new antipsychotics</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1997</YR>
<VL>7</VL>
<NO>Suppl 2</NO>
<PG>S227-8</PG>
<CY>Germany</CY>
<IDENTIFIERS MODIFIED="2013-01-30 10:00:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00047450" MODIFIED="2013-01-30 10:00:44 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00047450" YEAR="2009">
<REFERENCE MODIFIED="2013-01-30 09:51:25 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kasckow J, Lanouette N, Patterson T, Fellows I, Golshan S, Solorzano E, et al</AU>
<TI>Treatment of subsyndromal depressive symptoms in middle-aged and older adults with schizophrenia: effect on functioning</TI>
<SO>International Journal of Geriatric Psychiatry</SO>
<YR>2010</YR>
<VL>25</VL>
<PG>183-90</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="19711335"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE MODIFIED="2013-01-30 10:00:44 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zisook S, Kasckow JW, Golshan S, Fellows I, Solorzano E, Lehman D, et al</AU>
<TI>Citalopram augmentation for subsyndromal symptoms of depression in middle-aged and older outpatients with schizophrenia and schizoaffective disorder: a randomized controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2009</YR>
<VL>70</VL>
<NO>4</NO>
<PG>562-71</PG>
<IDENTIFIERS MODIFIED="2013-01-29 16:46:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="19192468"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT00531518" MODIFIED="2013-01-30 10:04:26 +0000" MODIFIED_BY="[Empty name]" NAME="NCT00531518" YEAR="2007">
<REFERENCE MODIFIED="2013-01-30 10:04:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT00531518</AU>
<TI>Early detection and intervention for the prevention of psychosis, a multisite study</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2007</YR>
<IDENTIFIERS MODIFIED="2013-01-30 10:04:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01041274" MODIFIED="2013-01-30 10:04:33 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01041274" YEAR="2009">
<REFERENCE MODIFIED="2013-01-30 10:04:33 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01041274</AU>
<TI>DECIFER: DEpression and Citalopram In First Episode Recovery</TI>
<SO>http://www.clinicaltrials.gov</SO>
<YR>2009</YR>
<IDENTIFIERS MODIFIED="2013-01-30 10:04:33 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-NCT01724372" MODIFIED="2013-01-30 10:04:42 +0000" MODIFIED_BY="[Empty name]" NAME="NCT01724372" YEAR="2012">
<REFERENCE MODIFIED="2013-01-30 10:04:42 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>NCT01724372</AU>
<TI>The role of antidepressants or antipsychotics in preventing psychosis</TI>
<SO>http://ClinicalTrials.gov/show/NCT01724372</SO>
<YR>2012</YR>
<IDENTIFIERS MODIFIED="2013-01-30 10:04:42 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ou-2007" MODIFIED="2013-01-30 10:04:50 +0000" MODIFIED_BY="[Empty name]" NAME="Ou 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-30 10:04:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ou G</AU>
<TI>A study on the adjunct effects of the anti-depression drug in treating schizophrenia with anxiety and depression symptom</TI>
<TO>&#25239;&#25233;&#37057;&#33647;&#23545;&#20276;&#28966;&#34385;&#25233;&#37057;&#30151;&#29366;&#31934;&#31070;&#20998;&#35010;&#30151;&#30340;&#36741;&#21161;&#27835;&#30103;&#25928;&#24212;</TO>
<SO>Chinese Journal of Health Psychology [&#20013;&#22269;&#20581;&#24247;&#24515;&#29702;&#23398;&#26434;&#24535;]</SO>
<YR>2007</YR>
<VL>15</VL>
<NO>2</NO>
<PG>159-60</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:04:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Overall-1961" MODIFIED="2013-01-30 10:04:56 +0000" MODIFIED_BY="[Empty name]" NAME="Overall 1961" YEAR="1961">
<REFERENCE MODIFIED="2013-01-30 10:04:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Hollister LE, Pokorny AD, Casey JF</AU>
<TI>Drug therapy in depressions: controlled evaluation of impramine, isocarboxazide, dextroamphetamine-amobarbital, and placebo</TI>
<SO>Clinical Pharmacology and Therapeutics</SO>
<YR>1961</YR>
<VL>3</VL>
<NO>1</NO>
<PG>16-22</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:04:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pierson-2006" MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" NAME="Pierson 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pierson K, Addington D, Addington J, Patten S</AU>
<TI>Serum monitoring of antipsychotic drug levels during concomitant administration of sertraline and antipsychotic medication</TI>
<SO>Canadian Journal of Psychiatry [Revue Canadienne de Psychiatrie]</SO>
<YR>2006</YR>
<VL>51</VL>
<NO>11</NO>
<PG>715-8</PG>
<CY>Canada</CY>
<IDENTIFIERS MODIFIED="2013-01-29 16:46:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="17121171"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Postel-1971" MODIFIED="2013-01-30 10:05:06 +0000" MODIFIED_BY="[Empty name]" NAME="Postel 1971" YEAR="1971">
<REFERENCE MODIFIED="2013-01-30 10:05:06 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Postel M, Czermack M, Postel J</AU>
<TI>Depressive forms of schizophrenia: experiment of treatment by chlorimipramine</TI>
<SO>L'Encephale</SO>
<YR>1971</YR>
<VL>60</VL>
<NO>4</NO>
<PG>312-34</PG>
<PB>Elsevier Masson SAS; France</PB>
<IDENTIFIERS MODIFIED="2013-01-30 10:05:06 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ren-2004" MODIFIED="2013-01-30 10:05:12 +0000" MODIFIED_BY="[Empty name]" NAME="Ren 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-30 10:05:12 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ren X, Zhen S, Fu X</AU>
<TI>A comparative study of amitriptyline plus cognitive therapy in the treatment of post-schizophrenic depression</TI>
<SO>Shanghai Archives of Psychiatry [&#19978;&#28023;&#31934;&#31070;&#21307;&#23398;] [&#19978;&#28023;&#31934;&#31070;&#37291;&#23416;]</SO>
<YR>2004</YR>
<VL>16</VL>
<NO>2</NO>
<PG>83-5</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:05:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Risch-2006" MODIFIED="2013-01-30 10:05:17 +0000" MODIFIED_BY="[Empty name]" NAME="Risch 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-30 10:05:17 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Risch SC, Horner MD, McGurk SR, Palecko S, Markowitz JS, Nahas Z, et al</AU>
<TI>Donepezil effects on mood in patients with schizophrenia and schizoaffective disorder</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>9</VL>
<NO>5</NO>
<PG>603-5</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:05:17 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ruan-2008" MODIFIED="2013-01-30 10:05:28 +0000" MODIFIED_BY="[Empty name]" NAME="Ruan 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-30 10:05:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ruan S, Zheng W, Du L</AU>
<TI>A control study of clozapine plus fluoxetine in schizophrenia with depressive symptoms</TI>
<TO>&#27695;&#27694;&#24179;&#32852;&#21512;&#27679;&#35199;&#27712;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#20276;&#25233;&#37057;&#30151;&#29366;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Clinical Psychosomatic Diseases [&#20020;&#24202;&#24515;&#36523;&#30142;&#30149;&#26434;&#24535;]</SO>
<YR>2008</YR>
<VL>14</VL>
<NO>3</NO>
<PG>211-3</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:05:22 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sheremata-2004" MODIFIED="2013-01-30 10:05:34 +0000" MODIFIED_BY="[Empty name]" NAME="Sheremata 2004" YEAR="2004">
<REFERENCE MODIFIED="2013-01-30 10:05:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sheremata S, Chen Y</AU>
<TI>Co-administration of atypical antipsychotics and antidepressants disturbs contrast detection in schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>2004</YR>
<VL>70</VL>
<NO>1</NO>
<PG>81-9</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:05:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Song-2003" MODIFIED="2013-01-30 10:05:39 +0000" MODIFIED_BY="[Empty name]" NAME="Song 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-30 10:05:39 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Song SY, Zhang RX</AU>
<TI>A comparative study of venlafaxien and amitriptyline in the treatment of post-schizophrenia depression</TI>
<SO>Medical Journal of Chinese Civil Administration</SO>
<YR>2003</YR>
<VL>15</VL>
<NO>7</NO>
<PG>394-6</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:05:39 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-St.-Jean1966" MODIFIED="2013-01-30 10:05:51 +0000" MODIFIED_BY="[Empty name]" NAME="St. Jean1966" YEAR="1966">
<REFERENCE MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>St. Jean A, Ban TA, Noe W</AU>
<TI>The effect of iminodibenzyls in the treatment of chronic psychotic patients</TI>
<SO>Current Therapeutic Research, Clinical and Experimental</SO>
<YR>1966</YR>
<VL>8</VL>
<PG>164-5</PG>
<EN>4</EN>
<CY>USA</CY>
<IDENTIFIERS MODIFIED="2013-01-29 16:46:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="4956547"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tang-2005" MODIFIED="2013-01-30 10:06:02 +0000" MODIFIED_BY="[Empty name]" NAME="Tang 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-30 10:06:02 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tang Y</AU>
<TI>Clinical comparative study of venlafaxine and chlorine the microphone Paming treatment of schizophrenia, depression</TI>
<TO>&#21338;&#20048;&#27427;&#21644;&#27695;&#21674;&#24085;&#26126;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;&#30340;&#20020;&#24202;&#23545;&#27604;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#21355;&#29983;</SO>
<YR>2005</YR>
<VL>6</VL>
<NO>21</NO>
<PG>39-40</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:06:02 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Terevnikov-2011" MODIFIED="2013-01-30 10:06:08 +0000" MODIFIED_BY="[Empty name]" NAME="Terevnikov 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-30 10:06:08 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Terevnikov V, Stenberg J-H, Tiihonen J, Joffe M, Burkin M, Tchoukhine E, et al</AU>
<TI>Add-on mirtazapine improves depressive symptoms in schizophrenia: A double-blind randomized placebo-controlled study with an open-label extension phase</TI>
<SO>Human Psychopharmacology</SO>
<YR>2011</YR>
<VL>26</VL>
<NO>3</NO>
<PG>188-93</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:06:08 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tong-2006" MODIFIED="2013-01-30 10:06:13 +0000" MODIFIED_BY="[Empty name]" NAME="Tong 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-30 10:06:13 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Tong J-M, Yang Z-C</AU>
<TI>The effect of the combination of sulpiride and fluoxetine in treatment of schizophrenia accompanied with depressive symptoms</TI>
<TO>&#33298;&#24517;&#21033;&#21512;&#24182;&#27679;&#35199;&#27712;&#27835;&#30103;&#20276;&#25233;&#37057;&#30151;&#29366;&#30340;&#31934;&#31070;&#20998;&#35010;&#30151;</TO>
<SO>Nervous Diseases and Mental Health [&#31070;&#32463;&#30142;&#30149;&#19982;&#31934;&#31070;&#21355;&#29983;]</SO>
<YR>2006</YR>
<VL>6</VL>
<NO>6</NO>
<PG>441-3</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:06:13 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Warawat-2544" MODIFIED="2013-01-30 10:06:20 +0000" MODIFIED_BY="[Empty name]" NAME="Warawat 2544" YEAR="2544">
<REFERENCE MODIFIED="2013-01-30 10:06:20 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Warawat C</AU>
<TI>Efficacy of olanzapine versus olanzapine combined with fluvozamine in acute-phase schizophrenia</TI>
<TO>&#3611;&#3619;&#3632;&#3626;&#3636;&#3607;&#3608;&#3636;&#3612;&#3621;&#3586;&#3629;&#3591; olanzapine &#3648;&#3611;&#3619;&#3637;&#3618;&#3610;&#3648;&#3607;&#3637;&#3618;&#3610;&#3585;&#3633;&#3610; olanzapine &#3619;&#3656;&#3623;&#3617;&#3585;&#3633;&#3610; fluvoxamine &#3651;&#3609;&#3650;&#3619;&#3588;&#3592;&#3636;&#3605;&#3648;&#3616;&#3607;&#3619;&#3632;&#3618;&#3632;&#3611;&#3619;&#3634;&#3585;&#3598;&#3629;&#3634;&#3585;&#3634;&#3619;</TO>
<SO>Journal of Psychiatric Association of Thailand</SO>
<YR>2544</YR>
<VL>46</VL>
<NO>4</NO>
<PG>275-87</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:06:20 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weissman-2012" MODIFIED="2013-01-30 10:06:28 +0000" MODIFIED_BY="[Empty name]" NAME="Weissman 2012" YEAR="2012">
<REFERENCE MODIFIED="2013-01-30 10:06:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weissman JF, Flint A, Meyers B, Ghosh S, Mulsant B, Rothschild A, et al</AU>
<TI>Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression</TI>
<SO>Psychiatry Research</SO>
<YR>2012</YR>
<VL>197</VL>
<NO>3</NO>
<PG>221-6</PG>
<IDENTIFIERS MODIFIED="2013-01-29 16:46:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="22464991"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wu-2006" MODIFIED="2013-01-30 10:06:34 +0000" MODIFIED_BY="[Empty name]" NAME="Wu 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-01-30 10:06:34 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wu X, Gao Z, Li Z</AU>
<TI>A control study of antidepressants adjuvant in schizophrenics with anxious and depressive symptoms</TI>
<TO>&#25239;&#25233;&#37057;&#21058;&#36741;&#21161;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#20276;&#28966;&#34385;&#25233;&#37057;&#30151;&#29366;&#24739;&#32773;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Clinical Psychosomatic Diseases [&#20020;&#24202;&#24515;&#36523;&#30142;&#30149;&#26434;&#24535;]</SO>
<YR>2006</YR>
<VL>12</VL>
<NO>4</NO>
<PG>258-9</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:06:34 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Xu-2007" MODIFIED="2013-01-30 10:06:40 +0000" MODIFIED_BY="[Empty name]" NAME="Xu 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-30 10:06:40 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Xu Q</AU>
<TI>Control study of citalopram and clomipramine in the treatment of schizophrenia Depression</TI>
<TO>&#35199;&#37214;&#26222;&#20848;&#21644;&#27695;&#19993;&#21674;&#21994;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>2007</YR>
<VL>20</VL>
<NO>2</NO>
<PG>101-2</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:06:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Yao-2005" MODIFIED="2013-01-30 10:06:45 +0000" MODIFIED_BY="[Empty name]" NAME="Yao 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-30 10:06:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>Yao W-H, Zhu Y-H, Li B, Feng W-C</AU>
<TI>Curative effect and safety of tatinol in improving the negative emotions of patients with schizophrenia</TI>
<TO>&#36798;&#20307;&#26391;&#25913;&#21892;&#31934;&#31070;&#20998;&#35010;&#30151;&#24739;&#32773;&#36127;&#24615;&#24773;&#32490;&#30340;&#30103;&#25928;&#21450;&#23433;&#20840;&#24615;</TO>
<SO>Modern Rehabilitation [&#29616;&#20195;&#24247;&#22797;]</SO>
<YR>2005</YR>
<VL>9</VL>
<NO>28</NO>
<PG>26-8</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:06:45 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhang-2005" MODIFIED="2013-01-30 10:06:51 +0000" MODIFIED_BY="[Empty name]" NAME="Zhang 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-30 10:06:51 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhang J-Q, Wang Q-L, Zhang Z</AU>
<TI>Treatment of 43 cases of post-schizophrenic depression with mianserin</TI>
<SO>Herald of Medicine [&#21307;&#33647;&#23548;&#25253;] [&#37291;&#34277;&#23566;&#22577;]</SO>
<YR>2005</YR>
<VL>24</VL>
<NO>10</NO>
<PG>889-90</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:06:51 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhou-2005" MODIFIED="2013-01-30 10:07:01 +0000" MODIFIED_BY="[Empty name]" NAME="Zhou 2005" YEAR="2005">
<REFERENCE MODIFIED="2013-01-30 10:07:01 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhou G</AU>
<TI>A clinical study of fluoxetine combined with supportive psychotherapy in post-schizophrenia depression</TI>
<SO>Journal of Clinical Psychosomatic Diseases [&#20020;&#24202;&#24515;&#36523;&#30142;&#30149;&#26434;&#24535;]</SO>
<YR>2005</YR>
<VL>11</VL>
<NO>3</NO>
<PG>209-10</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:07:01 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zisook-2010" MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" NAME="Zisook 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-29 16:46:19 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zisook S, Kasckow JW, Lanouette NM, Golshan S, Fellows I, Vahia I, et al</AU>
<TI>Augmentation with citalopram for suicidal ideation in middle-aged and older outpatients with schizophrenia and schizoaffective disorder who have subthreshold depressive symptoms: A randomized controlled trial</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>2010</YR>
<VL>71</VL>
<NO>7</NO>
<PG>915-22</PG>
<CY>United States</CY>
<IDENTIFIERS MODIFIED="2013-01-29 16:46:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="MEDLINE" VALUE="20361918"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5218__x5b88__x6885_-2009" MODIFIED="2013-01-30 10:07:26 +0000" MODIFIED_BY="[Empty name]" NAME="&#21016;&#23432;&#26757; 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-30 10:07:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21016;&#23432;&#26757;</AU>
<TI>Duloxetine and fluoxetine in the treatment of schizophrenia with depressive control study [Google Translate]</TI>
<TO>&#24230;&#27931;&#35199;&#27712;&#19982;&#27679;&#35199;&#27712;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Journal of Military Surgeon in Southwest China</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>5</NO>
<PG>840-1</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:07:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5218__x632f__x4e1c_-1995" MODIFIED="2013-01-30 10:09:09 +0000" MODIFIED_BY="[Empty name]" NAME="&#21016;&#25391;&#19996; 1995" YEAR="1995">
<REFERENCE MODIFIED="2013-01-30 10:09:09 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#21016;&#25391;&#19996;, &#21016;&#27427;</AU>
<TI>Alprazolam and imipramine in the treatment of schizophrenia efficacy and side effects of the depression, double-blind, controlled study</TI>
<TO>&#38463;&#26222;&#21777;&#20177;&#19982;&#19993;&#21674;&#21994;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;&#30340;&#30103;&#25928;&#21644;&#21103;&#21453;&#24212;&#21452;&#30450;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Shandong Archives of Psychiatry [&#23665;&#19996;&#31934;&#31070;&#21307;&#23398;]</SO>
<YR>1995</YR>
<VL>2</VL>
<PG>38-9</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:07:40 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5468__x5e7f__x7389_-2011" MODIFIED="2013-01-30 10:07:56 +0000" MODIFIED_BY="[Empty name]" NAME="&#21608;&#24191;&#29577; 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-30 10:07:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#21608;&#24191;&#29577;, &#33635;&#25935;</AU>
<TI>Paroxetine combined with lithium in 24 cases of refractory depression efficacy</TI>
<TO>&#24085;&#32599;&#35199;&#27712;&#21512;&#24182;&#30899;&#37240;&#38146;&#23545;24&#20363;&#38590;&#27835;&#24615;&#25233;&#37057;&#30151;&#30103;&#25928;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2011</YR>
<VL>23</VL>
<NO>15</NO>
<PG>1899-90</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:07:56 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5b59__x797a__x7ae0_-2000" MODIFIED="2013-01-30 10:09:21 +0000" MODIFIED_BY="[Empty name]" NAME="&#23385;&#31098;&#31456; 2000" YEAR="2000">
<REFERENCE MODIFIED="2013-01-30 10:09:21 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#23385;&#31098;&#31456;, &#20313;&#22269;&#27721;, &#24352;&#25945;&#19996;, &#19969;&#22269;&#23433;</AU>
<TI>Control study of domestic venlafaxine and amitriptyline in the treatment of schizophrenia, depression</TI>
<TO>&#22269;&#20135;&#19975;&#25289;&#27861;&#26032;&#21644;&#38463;&#31859;&#26367;&#26519;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Chinese Journal of Nervous and Mental Diseases</SO>
<YR>2000</YR>
<VL>26</VL>
<NO>5</NO>
<PG>301-2</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:09:21 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x4f20__x6d77_-2007" MODIFIED="2013-01-30 10:09:28 +0000" MODIFIED_BY="[Empty name]" NAME="&#24352;&#20256;&#28023; 2007" YEAR="2007">
<REFERENCE MODIFIED="2013-01-30 10:09:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#20256;&#28023;</AU>
<TI>Depression controlled study of sertraline and venlafaxine in the treatment of schizophrenia</TI>
<TO>&#33293;&#26354;&#26519;&#19982;&#19975;&#25289;&#27861;&#26032;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Chinese Journal of Primary Medicine Pharmacy [&#20013;&#22269;&#22522;&#23618;&#21307;&#33647;]</SO>
<YR>2007</YR>
<VL>14</VL>
<NO>2</NO>
<PG>286-8</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:09:28 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x5f20__x65b0__x5e73_-2009" MODIFIED="2013-01-30 10:09:45 +0000" MODIFIED_BY="[Empty name]" NAME="&#24352;&#26032;&#24179; 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-30 10:09:45 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#24352;&#26032;&#24179;, &#21016;&#37329;&#40527;, &#20313;&#24535;&#21018;, &#24196;&#24314;&#20891;, &#30333;&#39062;, &#33539;&#21191;</AU>
<TI>Shun Qi Decoction Treating depression after 30 cases of schizophrenia [Google Translate]</TI>
<TO>&#39034;&#27668;&#35299;&#37057;&#27748;&#21152;&#20943;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;30&#20363;</TO>
<SO>Henan Traditional Chinese Medicine</SO>
<YR>2009</YR>
<VL>29</VL>
<NO>10</NO>
<PG>1003-4</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:09:45 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x674e__x5170__x82b3_-2010" MODIFIED="2013-01-30 10:09:50 +0000" MODIFIED_BY="[Empty name]" NAME="&#26446;&#20848;&#33459; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-30 10:09:50 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#26446;&#20848;&#33459;, &#26361;&#38738;, &#38472;&#23431;&#26198;</AU>
<TI>Venlafaxine and amitriptyline combined controlled study of risperidone in the treatment of schizophrenia with depressive symptoms</TI>
<TO>&#25991;&#25289;&#27861;&#36763;&#19982;&#38463;&#31859;&#26367;&#26519;&#20998;&#21035;&#21512;&#24182;&#21033;&#22521;&#37230;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#20276;&#25233;&#37057;&#30151;&#29366;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#23454;&#29992;&#20020;&#24202;&#21307;&#23398;</SO>
<YR>2010</YR>
<VL>11</VL>
<NO>08</NO>
<PG>31-4</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:09:50 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x76ae__x73a5__x73a5_-2010" MODIFIED="2013-01-30 10:09:58 +0000" MODIFIED_BY="[Empty name]" NAME="&#30382;&#29605;&#29605; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-30 10:09:58 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#30382;&#29605;&#29605;</AU>
<TI>Citalopram and venlafaxine in the treatment of schizophrenia, depression-control study</TI>
<TO>&#35199;&#37214;&#26222;&#20848;&#19982;&#25991;&#25289;&#27861;&#36763;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#23454;&#29992;&#31070;&#32463;&#30142;&#30149;&#26434;&#24535;</SO>
<YR>2010</YR>
<VL>13</VL>
<NO>24</NO>
<PG>34-5</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:09:58 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x803f__x7389__x8fb0_-2008" MODIFIED="2013-01-30 10:10:05 +0000" MODIFIED_BY="[Empty name]" NAME="&#32831;&#29577;&#36784; 2008" YEAR="2008">
<REFERENCE MODIFIED="2013-01-30 10:10:05 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#32831;&#29577;&#36784;, &#33931;&#29577;&#20848;, &#32831;&#23005;&#38686;</AU>
<TI>Comparative study of citalopram and fluoxetine in the treatment of mental illness, depression and residual depression</TI>
<TO>&#35199;&#37214;&#26222;&#20848;&#19982;&#27679;&#35199;&#27712;&#27835;&#30103;&#31934;&#31070;&#30149;&#21518;&#25233;&#37057;&#21450;&#27531;&#30041;&#26399;&#25233;&#37057;&#30340;&#23545;&#27604;&#30740;&#31350;</TO>
<SO>&#20013;&#22269;&#21307;&#33647;&#23548;&#25253;</SO>
<YR>2008</YR>
<VL>5</VL>
<NO>25</NO>
<PG>65-6</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:10:05 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x83ab__x8fea_-2011" MODIFIED="2013-01-30 10:10:18 +0000" MODIFIED_BY="[Empty name]" NAME="&#33707;&#36842; 2011" YEAR="2011">
<REFERENCE MODIFIED="2013-01-30 10:10:18 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#33707;&#36842;</AU>
<TI>Citalopram treatment of schizophrenia and depression</TI>
<TO>&#35199;&#37214;&#26222;&#20848;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;&#30340;&#30103;&#25928;&#35266;&#23519;</TO>
<SO>&#20013;&#22269;&#27665;&#24247;&#21307;&#23398;</SO>
<YR>2011</YR>
<VL>23</VL>
<NO>16</NO>
<PG>2003-4</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:10:18 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x8521__x5fd7__x5229_-2002" MODIFIED="2013-01-30 10:10:26 +0000" MODIFIED_BY="[Empty name]" NAME="&#34081;&#24535;&#21033; 2002" YEAR="2002">
<REFERENCE MODIFIED="2013-01-30 10:10:26 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#34081;&#24535;&#21033;, &#34081;&#24535;&#21191;, &#38472;&#33395;&#29618;</AU>
<TI>Sulpiride merger doxepin in the treatment of clinical analysis of schizophrenia with depressive symptoms</TI>
<TO>&#33298;&#24517;&#21033;&#21512;&#24182;&#22810;&#34385;&#24179;&#27835;&#30103;&#20276;&#25233;&#37057;&#30151;&#29366;&#31934;&#31070;&#20998;&#35010;&#30151;&#20020;&#24202;&#20998;&#26512;</TO>
<SO>Medical Journal of Chinese Civil Administration</SO>
<YR>2002</YR>
<VL>14</VL>
<NO>4</NO>
<PG>216-7</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:10:26 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x97e9__x536b__x519b_-2009" MODIFIED="2013-01-30 10:10:43 +0000" MODIFIED_BY="[Empty name]" NAME="&#38889;&#21355;&#20891; 2009" YEAR="2009">
<REFERENCE MODIFIED="2013-01-30 10:10:43 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="OTHER">
<AU>&#38889;&#21355;&#20891;, &#23385;&#26690;&#33655;</AU>
<TI>Sulpiride and buspirone hydrochloride tablets in the treatment of schizophrenia and the effect of depression after double-blind controlled study side effects [Google Translate]</TI>
<TO>&#33298;&#24517;&#21033;&#19982;&#30416;&#37240;&#19969;&#34746;&#29615;&#37230;&#29255;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;&#30340;&#30103;&#25928;&#21644;&#21103;&#21453;&#24212;&#21452;&#32915;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>&#36797;&#23425;&#20013;&#21307;&#33647;&#22823;&#23398;&#23398;&#25253;</SO>
<YR>2009</YR>
<VL>11</VL>
<NO>7</NO>
<PG>131</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:10:43 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9a6c__x519b_-2010" MODIFIED="2013-01-30 10:11:03 +0000" MODIFIED_BY="[Empty name]" NAME="&#39532;&#20891; 2010" YEAR="2010">
<REFERENCE MODIFIED="2013-01-30 10:11:03 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#39532;&#20891;, &#21016;&#27704;&#20041;, &#27575;&#26397;&#36745;, &#24352;&#23195;</AU>
<TI>Escitalopram and maprotiline treatment of depression after control study of schizophrenia [Google Translate]</TI>
<TO>&#33406;&#21496;&#35199;&#37214;&#26222;&#20848;&#21644;&#39532;&#26222;&#26367;&#26519;&#27835;&#30103;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;&#30340;&#23545;&#29031;&#30740;&#31350;</TO>
<SO>Nei Moivgol Medical Journal</SO>
<YR>2010</YR>
<VL>42</VL>
<NO>2</NO>
<PG>171-3</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:11:03 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-_x9a6c__x632f__x6b66_-2003" MODIFIED="2013-01-30 10:11:23 +0000" MODIFIED_BY="[Empty name]" NAME="&#39532;&#25391;&#27494; 2003" YEAR="2003">
<REFERENCE MODIFIED="2013-01-30 10:11:23 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>&#39532;&#25391;&#27494;, &#24352;&#29233;&#26223;</AU>
<TI>133 cases of fluoxetine in the treatment of schizophrenia, depression</TI>
<TO>&#27679;&#35199;&#27712;&#27835;&#30103;&#31934;&#31070;&#20998;&#35010;&#30151;&#21518;&#25233;&#37057;133&#20363;</TO>
<SO>Chinese Journal of Clinical Rehabilitation</SO>
<YR>2003</YR>
<VL>24</VL>
<PG>3333</PG>
<IDENTIFIERS MODIFIED="2013-01-30 10:11:12 +0000" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-03-12 14:13:00 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-03-12 14:13:00 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecing skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bech-2000" NAME="Bech 2000" TYPE="JOURNAL_ARTICLE">
<AU>Bech P, Cialdella MC, Haugh MC, Birkett MA, Hours A, Boissel JP, Tollefons GD</AU>
<TI>Meta-analysis of randomised controlled trials of fluoxetine v placebo and tricyclic antidepressants in the short term treatment of major depression</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>176</VL>
<PG>421-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Beck-1961" NAME="Beck 1961" TYPE="JOURNAL_ARTICLE">
<AU>Beck AT, Ward CH, Mendelsohn M, Mock J, Erbaugh J</AU>
<TI>An inventory for measuring depression</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1961</YR>
<VL>4</VL>
<PG>561-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clarke-2002" MODIFIED="2013-01-30 10:14:48 +0000" MODIFIED_BY="[Empty name]" NAME="Clarke 2002" TYPE="OTHER">
<AU>Clarke M, Oxman AD</AU>
<TI>Cochrane Collaboration Handbook</TI>
<SO>The Cochrane Library</SO>
<YR>2002</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Feighner-1972" NAME="Feighner 1972" TYPE="JOURNAL_ARTICLE">
<AU>Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munoz R</AU>
<TI>Diagnostic criteria for use in psychiatric research</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1972</YR>
<VL>26</VL>
<PG>57-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freemantle-2000" NAME="Freemantle 2000" TYPE="JOURNAL_ARTICLE">
<AU>Freemantle N, Anderson IM, Young P</AU>
<TI>Predictive value of pharmacological activity for the relative efficacy of antidepressant drugs. Meta-regression analysis</TI>
<SO>British Journal of Psychiatry</SO>
<YR>2000</YR>
<VL>177</VL>
<PG>292-302</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>Early clinical drug evaluation (ECDEU) assessment manual for psychopharmacology</SO>
<YR>1976</YR>
<PB>National Institute of Mental Health</PB>
<CY>Washington DC</CY>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="Publication No.76-338"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>A rating scale for depression</TI>
<SO>Journal of Neurology Neurosurgery and Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Knights-1981" NAME="Knights 1981" TYPE="JOURNAL_ARTICLE">
<AU>Knights A, Hirsch SR</AU>
<TI>'Revealed' depression and drug treatment of schizophrenia</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1981</YR>
<VL>38</VL>
<PG>806-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martin-1985" NAME="Martin 1985" TYPE="JOURNAL_ARTICLE">
<AU>Martin RL, Cloninger CR, Guze SB, Clayton PJ</AU>
<TI>Frequency and differential diagnosis of depressive syndromes in schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1985</YR>
<VL>46</VL>
<PG>9-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Miles-1977" NAME="Miles 1977" TYPE="JOURNAL_ARTICLE">
<AU>Miles CP</AU>
<TI>Conditions predisposing to suicide: a review</TI>
<SO>Journal of Nervous and Mental Disease</SO>
<YR>1977</YR>
<VL>164</VL>
<PG>231-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Schultz KF, Altman DG for the CONSORT Group</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials</TI>
<SO>Lancet</SO>
<YR>2001</YR>
<VL>357</VL>
<PG>1191-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulholland-2000" NAME="Mulholland 2000" TYPE="JOURNAL_ARTICLE">
<AU>Mulholland C, Cooper S</AU>
<TI>The symptom of depression in schizophrenia and its management</TI>
<SO>Advances in Psychiatric Treatment</SO>
<YR>2000</YR>
<VL>6</VL>
<PG>169-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The brief psychiatric rating scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Plasky-1991" NAME="Plasky 1991" TYPE="JOURNAL_ARTICLE">
<AU>Plasky P</AU>
<TI>Antidepressant usage in schizophrenia</TI>
<SO>Schizophrenia Bulletin</SO>
<YR>1991</YR>
<VL>17</VL>
<NO>4</NO>
<PG>649-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raskin-1970" NAME="Raskin 1970" TYPE="JOURNAL_ARTICLE">
<AU>Raskin A, Schulterbrandt JG, Reating N, McKeon JJ</AU>
<TI>Differential response to chlorpromazine, imipramine, and placebo. A study of subgroups of hospitalized depressed patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1970</YR>
<VL>23</VL>
<PG>164-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roy-1986" NAME="Roy 1986" TYPE="JOURNAL_ARTICLE">
<AU>Roy A</AU>
<TI>Depression, attempted suicide, and suicide in patients with chronic schizophrenia</TI>
<SO>Psychiatric Clinics of North America</SO>
<YR>1986</YR>
<VL>9</VL>
<PG>193-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Siris-1987b" NAME="Siris 1987b" TYPE="JOURNAL_ARTICLE">
<AU>Siris SG</AU>
<TI>Akinesia and post psychotic depression: a difficult differential diagnosis</TI>
<SO>Journal of clinical psychiatry</SO>
<YR>1987</YR>
<VL>48</VL>
<PG>240-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zung-1993" NAME="Zung 1993" TYPE="JOURNAL_ARTICLE">
<AU>Zung WW, Broadhead WE, Roth ME</AU>
<TI>Prevalence of depressive symptoms in primary care</TI>
<SO>Journal of Family Practice</SO>
<YR>1993</YR>
<VL>37</VL>
<PG>337-44</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-01-30 10:19:09 +0000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Becker-1983">
<CHAR_METHODS>
<P>Allocation: randomised, computer generated code.<BR/>Blindness: double, matched capsules.<BR/>Duration: 4 weeks (preceded by 2 weeks medication free).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM II &amp; RDC), with depression (RDC Major depressive syndrome &amp; HAM-D 3/4 (depressed) or 3/4 on work &amp; activities items (anergic)).<BR/>N=52.<BR/>Sex: female 17 male 35.<BR/>Age: mean 38 years.<BR/>History: both chronic &amp; newly admitted.<BR/>Setting: hospital.<BR/>Phase: no information.<BR/>Medication history: no information.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Chlorpromazine + imipramine: mean dose 156 mg/day. N=28.<BR/>2. Thiothixene + placebo. N=24.<BR/>Both groups: benztropine and diphenhydramine for sleep.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: BPRS, HAM-D. <BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>General: CGI (no results by group).<BR/>Side effects: no results by group.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>There were different antipsychotics in the two groups.<BR/>30 people anergic not depressed on HAM-D.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Dufresne-1988">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 10 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM III) with depression (DSM III major depressive episode for preceding 2 weeks, prominent dysphoric mood &amp; HAM-D &gt;18).<BR/>N=38.<BR/>Sex: female 14, male 24.<BR/>Age: mean 41 years.<BR/>History: mean duration of current exacerbation 18 weeks, stabilised on thiothixene.<BR/>Setting: hospital.<BR/>Phase: no information.<BR/>Medication history: no information.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Thiothixene + bupropion: dose mean 446 mg/day SD 413. N=19.<BR/>2. Thiothixene + placebo. N=19.<BR/>Both groups thiothixene: dose mean 22 mg/day (SD 16).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: BPRS, HAM-D (4 weeks).<BR/>Leaving the study early.</P>
<P>Unable to use - <BR/>General: CGI (no means).<BR/>Mental state: BPRS, HAM-D (10 weeks, &gt;50 loss to follow up).<BR/>Side effects: AIMS, REPS (no means).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>
<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Hogarty-1995">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: "double".<BR/>Duration: 12 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (RDC), depression (Raskin Depression &gt;7 (persistent distress for 3 weeks)).<BR/>N=33.<BR/>Sex: female 12, male 21.<BR/>Age: mean ~ 32 years.<BR/>History: chronic patients. <BR/>Setting: outpatients.<BR/>Phase: chronic distress or defect state for at least 3 months.<BR/>Medication history: early phases of study optimised use of neuroleptics and anticholinergics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1: Desipramine: dose 50mg/day increased to 150 mg. N=16.<BR/>2: Placebo. N=17.<BR/>Both groups: : fluphenazine decanoate, benztropine mesylate.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical Improvement: (CGI "much improved")</P>
<P>Unable to use -<BR/>Mental state: BPRS , BDI, Covi anxiety scale, Taylor anxiety scale.<BR/>No SDs given</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Assumed zero dropouts. ITT analysis found statistically significant benefit for antidepressant on BDI (P=0.04) and BPRS (P=0.03).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Jasovic-1996">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV), depression (HAM(D) &gt;=16).<BR/>N=52.<BR/>Sex: no information.<BR/>Age: no information.<BR/>History: no information.<BR/>Phase: no information.<BR/>Setting: no information.<BR/>Medication history: no information.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Amitryptilline. N=12.<BR/>2. Mianserin N=11.<BR/>3. Moclobeminde. N=14.<BR/>4. Placebo. N=15.<BR/>Both groups: unspecified neuroleptic medication.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: HAM(D)</P>
<P>Unable to use -<BR/>Mental state: BPRS (no means or SDs).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstract only.<BR/>All antidepressant groups (1,2,&amp; 3) combined in results.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Johnson-1981">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, identical placebo tablets.<BR/>Duration: 5 weeks.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (positive Feighner or Schneiderian symptoms), depression (lowered mood state, BDI or HAM-D &gt;15).<BR/>N= 50. <BR/>Sex: female 27, male 23.<BR/>Age: mean ~ 31 years. <BR/>History: clinically depressed for 1 week, two or more previous admissions for schizophrenia.<BR/>Setting: hospital.<BR/>Phase: those with active schizophrenic symptoms excluded.<BR/>Medication history: "free from extrapyramidal signs".</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Nortriptyline: dose 75-150 mg/day. N=25.<BR/>2. Placebo. N=25.<BR/>Both groups: fluphenazine decanoate or flupenthixol decanoate, oral anti-parkinsonian drugs and benzodiazepines.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: HAM-D. <BR/>Clinical recovery (HAM-D reduction 33%).<BR/>SIde effects.</P>
<P>Unable to use -<BR/>Mental state: BPRS (no results).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Assumed zero dropouts.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kramer-1989">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, no further details.<BR/>Duration: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III, BPRS &gt;30), depression (RDC major depressive episode. HAM-D &gt;17).<BR/>N=58.<BR/>Age: mean ~ 37 years. <BR/>History: chronically psychotic, ~ 15 years since diagnosis.<BR/>Setting: hospital.<BR/>Phase: 5 weeks after acute psychosis onset.<BR/>Medication history: medication free for 2 weeks then 5 weeks haloperidol and benztropine optimised to minimise EPS.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Desimipramine hydrochloride: dose 3.5 mg/kg/day. N=22.<BR/>2. Amitryptilline: dose 3.5mg/Kg/day. N=22.<BR/>3. Placebo. N=22.<BR/>Both groups: haloperidol 0.4mg/kg/day, benztropine 6 mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental State: HAM-D &amp; BPRS.<BR/>Leaving the study early.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>66 randomised and assume that 22 were randomised to each group.<BR/>Did not perform ITT analysis: 54 people of 66 randomised included in results.<BR/>Group 1 and 2 combined in results.<BR/>Checked compliance with plasma measurement.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Kurland-1981">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double, identical placebo tablets.<BR/>Duration: 4 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (not otherwise specified), depression (HAM-D &gt;18).<BR/>N=28.<BR/>Sex: no information.<BR/>Age: range 19-53 years.<BR/>History: no information.<BR/>Setting: no information.<BR/>Phase: no information.<BR/>Medication history: stabilised for 2 wks on antipsychotic.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Haloperidol or chlorpromazine + viloxazine: dose 150-300mg depending upon response. N=14.<BR/>2. Haloperidol or chlorpromazine + placebo. N=14.<BR/>Both groups: haloperidol dose 6-15mg/day, chlorpromazine dose 75-300mg/day.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.</P>
<P>Unable to use -<BR/>Global improvement: CGI (no means or SDs).<BR/>Mental state: BPRS, HAM(D), Zung Self Rating Depression Scale (no means or SDs).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Viloxazine v placebo comparison reported for dropouts.<BR/>Assumed 7 people randomised to each group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Mulholland-1997">
<CHAR_METHODS>
<P>Allocation: randomised, computer generated numbers.<BR/>Blindness: double, identical placebo capsules.<BR/>Duration: 8 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III-R), depression (&gt;= 3 on BPRS depression and &gt;= 15 on BDI).<BR/>N=26.<BR/>Sex: female 10, male 16. <BR/>Age: mean 38 years. <BR/>History: duration ill ~ 15 years.<BR/>Setting: out-patients.<BR/>Phase: stable, no admission to hospital in previous 6 months.<BR/>Medication History: people with significant EPS excluded. All on neuroleptic medication. 16 of the 26 were on anticholinergics.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Sertraline: dose 50 mg/day 4 weeks, 100 mg/day next 4 weeks if tolerated. N=13.<BR/>2. Placebo. N=13.<BR/>Both groups: neuroleptic and anticholinergic.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental State: HAM(D), BPRS.<BR/>Leaving the study early.<BR/>Clinical recovery: CGI minimal or better improvement.</P>
<P>Unable to use - <BR/>Mental state: BDI (HAM(D) used in preference).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>ITT analysis performed.<BR/>Unpublished results provided by authors.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Prusoff-1979">
<CHAR_METHODS>
<P>Allocation: randomised no further details.<BR/>Blindness: double, identical placebo.<BR/>Duration: 6 months.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM II &amp; NHSI (4/16 symptoms), depression (RDS &gt;7).<BR/>N=40.<BR/>Sex: "about half male".<BR/>Age: range 18-65 years.<BR/>History: no details.<BR/>Setting: out-patients.<BR/>Phase: were treated with perphenazine for a month before randomisation.<BR/>Medication history: perphenazine optimised to minise psychotic symptoms.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Amitriptyline hydrochloride: dose 100-200mg/day. N=20.<BR/>2. Placebo. N=20.<BR/>Both groups: perphenazine.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Clinical recovery: global psychiatric status moderate improvement.<BR/>Leaving the study early.</P>
<P>Unable to use -<BR/>Mental state: BPRS, HAM(D), RDS (no SDs).<BR/>Quality of life: SCL-90 (no SDs).<BR/>Social functioning: Social Adjustment Scale (no SDs).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>High dropout rate of over 50% at 6 months. Did not perform ITT analysis, report on 24 of 40 people at 4 months. Results found statistically significant improvement for antidepressant group at 4 months for Raskin depression scale and HAM(D) anxiety-depression subscale.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Singh-1978">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double.<BR/>Duration: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM III &amp; RDC), depression (RDC, HAM(D) &gt;18).<BR/>N=60.<BR/>Sex: female 26, male 34.<BR/>Age: mean ~ 43 years.<BR/>History: mean length of illness ~18 years. <BR/>Setting: hospital.<BR/>Phase: "chronic hospitalised schizophrenic patients".<BR/>Medication history: 5 week stabilisation on phenothiazine, and anticholinergic if prescribed.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Trazodone: dose 150-300mg/day. N=30.<BR/>2. Placebo. N=30.<BR/>Both groups: phenothiazine and anticholinergic.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: HAM(D), BPRS.<BR/>Clinical Recovery: CGI "improved". <BR/>Side effects.</P>
<P>Unable to use -<BR/>Behaviour: Nurse Observation Scale for Inpatient Evaluation (no SDs).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Assumed no drop outs.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Siris-1987">
<CHAR_METHODS>
<P>Allocation: randomised, no further details.<BR/>Blindness: double.<BR/>Duration: 6 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia or schizoaffective (RDC), depression (RDC 4 weeks, HAM(D) &gt;12).<BR/>N=33. <BR/>Sex: female 17, male 16. <BR/>Age: mean ~ 31 years.<BR/>History: no information.<BR/>Setting: 28 out-patients 5 in-patients.<BR/>Phase: non-psychotic or residually psychotic.<BR/>Medication history: depression not responsive to 1 wk of benztropine 6mg/day.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Imipramine: dose 200mg/day. N=17<BR/>2. Placebo. N=16<BR/>Both groups: fluphenazine decanoate, benztropine mesylate unchanged.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state: HAM(D) (extracted from SADS).</P>
<P>Unable to use -<BR/>Global impression: Global Assessment Scale (no SDs). Mental state: other items of SADS (not comparable with BPRS results).<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Non-ITT analysis. 2 drop outs from placebo group.<BR/>Also checked compliance with plasma measurement.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>Assessments: <BR/>HAM-D: Hamilton Rating Scale for Depression<BR/>BPRS: Brief Psychiatric Rating Scale.<BR/>BDI: Beck Depression Inventory<BR/>RDS: Raskin Depression Scale <BR/>CGI: Clinical Global Impression Scale<BR/>SCL-90 Symptom checklist</P>
<P>Diagnostic criteria<BR/>RDC: Research Diagnostic Criteria<BR/>DSM-II Diagnostic and Statistical Manual 2nd edition<BR/>DSM-III Diagnostic and Statistical Manual 3rd edition<BR/>DSM-III-R Diagnostic and Statistical Manual. 3rd edition revised.<BR/>NHSI: New Haven Schizophrenia Index</P>
<P>Statistical abbreviations:<BR/>SD standard deviation<BR/>ITT Intention to treat analysis</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Arango-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Arato-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Benkert-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: with schizophrenia and depression.<BR/>Intervention: no placebo.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Duval-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: with schizophrenia and depression.<BR/>Intervention: no antidepressant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eikmeier-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goff-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goff-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Goode-1983">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Hiemke-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Joffe-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kirli-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia and depression.<BR/>Intervention: no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Knights-1979">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia.<BR/>Intervention: no antidepressant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Koreen-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia and depression.<BR/>Intervention: no antidepressant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Krakowski-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia and depression.<BR/>Intervention: no antidepressant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lee-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia and depression.<BR/>Intervention: no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Muller-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia and depression.<BR/>Intervention: no placebo group.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Salokangas-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Silver-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Silver-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia and depression.<BR/>Intervention: no antidepressant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1987a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia and depression.<BR/>Intervention: no antidepressant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Participants: randomised.<BR/>Intervention: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1993">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia and depression, but also with substance abuse.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Siris-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia and depression.<BR/>Intervention: imipramine and placebo.<BR/>Outcome: study of antidepressant maintenance.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Spina-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thakore-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tollefson-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia and depression.<BR/>Intervention: no antidepressant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tollefson-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia and depression.<BR/>Intervention: no antidepressant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tollefson-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: schizophrenia and depression.<BR/>Intervention: no antidepressant.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Waehrens-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: not depressed.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2013-01-30 10:19:09 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Addington-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:08 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Addington-2002a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:10 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Berk-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:11 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:13 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Blumberger-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:13 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chen-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:15 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:17 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dawes-2012">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:17 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Eli-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:18 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:20 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fitzgerald-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:20 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Friedman-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:21 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Geddes-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:23 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gerson-1970">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:24 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:26 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gunby-1966">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:26 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:27 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Han-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:27 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:30 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hu-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:30 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:31 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ISRCTN42305247-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:42 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:45 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Izakova-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:45 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Izakova-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:46 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jasovic_x002d_Gasic-1990">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:47 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jasovic_x002d_Gasic-1991">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:49 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:50 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Jin-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:50 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kasckow-2001">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:52 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kasckow-2010a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:53 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:55 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kim-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:55 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krumholz-1968">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:56 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:17:58 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lehmann-1970">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:17:58 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:02 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:03 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Liu-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:03 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mulholland-1997a">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:05 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:06 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mulholland-1998">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:06 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:08 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mulholland-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:08 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:10 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Muller-1997">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:10 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:11 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00047450">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:11 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:12 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT00531518">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:12 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:15 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01041274">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:15 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:16 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-NCT01724372">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:16 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:18 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ou-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:18 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:19 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Overall-1961">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:19 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:21 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pierson-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:21 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:23 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Postel-1971">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:23 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:24 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ren-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:24 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:25 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Risch-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:25 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:28 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ruan-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:28 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:29 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Sheremata-2004">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:29 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:31 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Song-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:31 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:32 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-St.-Jean1966">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:32 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:35 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tang-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:35 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Terevnikov-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:36 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:37 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tong-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:37 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Warawat-2544">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:39 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:39 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weissman-2012">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:39 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:41 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Wu-2006">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:41 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:42 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Xu-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:42 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:44 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Yao-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:44 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:46 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhang-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:46 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:47 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zhou-2005">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:47 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:48 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Zisook-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:48 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:49 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5218__x5b88__x6885_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:49 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:52 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5218__x632f__x4e1c_-1995">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:52 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:53 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5468__x5e7f__x7389_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:53 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:54 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5b59__x797a__x7ae0_-2000">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:54 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:56 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x4f20__x6d77_-2007">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:56 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:57 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x5f20__x65b0__x5e73_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:57 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:18:59 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x674e__x5170__x82b3_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:18:59 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:19:01 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x76ae__x73a5__x73a5_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:19:01 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:19:02 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x803f__x7389__x8fb0_-2008">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:19:02 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:19:04 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x83ab__x8fea_-2011">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:19:04 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:19:05 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x8521__x5fd7__x5229_-2002">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:19:05 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:19:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x97e9__x536b__x519b_-2009">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:19:07 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:19:07 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9a6c__x519b_-2010">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:19:07 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<AWAITING_CHAR MODIFIED="2013-01-30 10:19:09 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-_x9a6c__x632f__x6b66_-2003">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES MODIFIED="2013-01-30 10:19:09 +0000" MODIFIED_BY="[Empty name]">
<P>To be assessed.</P>
</CHAR_NOTES>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Becker-1983">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Dufresne-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Hogarty-1995">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Jasovic-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Johnson-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kramer-1989">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Kurland-1981">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Mulholland-1997">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Prusoff-1979">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Singh-1978">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Siris-1987">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>ANY ANTIDEPRESSANT + ANTIPSYCHOTIC vs PLACEBO + ANTIPSYCHOTIC</NAME>
<DICH_OUTCOME CHI2="5.355027444197814" CI_END="-0.1340223854586093" CI_START="-0.3885994242861702" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.2613109048723898" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="73" I2="25.303837530580537" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" NO="1" P_CHI2="0.2527697792640027" P_Q="1.0" P_Z="5.731164350341056E-5" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="104" TOTAL_2="105" WEIGHT="100.0" Z="4.023614735061557">
<NAME>No important clinical response (Global Psychiatric Status, CGI, or significant reduction in HAM-D)</NAME>
<GROUP_LABEL_1>Antidepressant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.17162995139347603" CI_START="-0.4510417160993583" EFFECT_SIZE="-0.13970588235294112" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="50" O_E="0.0" SE="0.15884773200027882" STUDY_ID="STD-Hogarty-1995" TOTAL_1="16" TOTAL_2="17" VAR="0.025232601961632406" WEIGHT="15.777262180974477"/>
<DICH_DATA CI_END="0.154282937027577" CI_START="-0.394282937027577" EFFECT_SIZE="-0.12" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="51" O_E="0.0" SE="0.13994284547628721" STUDY_ID="STD-Johnson-1981" TOTAL_1="25" TOTAL_2="25" VAR="0.019583999999999997" WEIGHT="23.926914153132252"/>
<DICH_DATA CI_END="-0.2145632241744479" CI_START="-0.8623598527486291" EFFECT_SIZE="-0.5384615384615385" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="52" O_E="0.0" SE="0.16525727862448453" STUDY_ID="STD-Mulholland-1997" TOTAL_1="13" TOTAL_2="13" VAR="0.027309968138370506" WEIGHT="12.44199535962877"/>
<DICH_DATA CI_END="0.10205073579033952" CI_START="-0.5020507357903395" EFFECT_SIZE="-0.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="53" O_E="0.0" SE="0.1541103500742244" STUDY_ID="STD-Prusoff-1979" TOTAL_1="20" TOTAL_2="20" VAR="0.02375" WEIGHT="19.1415313225058"/>
<DICH_DATA CI_END="-0.13262317229426185" CI_START="-0.6007101610390715" EFFECT_SIZE="-0.36666666666666664" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="54" O_E="0.0" SE="0.11941214033447042" STUDY_ID="STD-Singh-1978" TOTAL_1="30" TOTAL_2="30" VAR="0.01425925925925926" WEIGHT="28.7122969837587"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="13.307735690112802" CI_END="-0.5484046439759478" CI_START="-3.772022677474208" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.160213660725078" ESTIMABLE="YES" I2="62.4278681480364" I2_Q="74.32782915764365" ID="CMP-001.02" NO="2" P_CHI2="0.02065946399401508" P_Q="0.048422354448187654" P_Z="0.008618552717167964" Q="3.8952685619795977" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="110" UNITS="" WEIGHT="100.00000000000001" Z="2.6268254674936915">
<NAME>Mental state: 1a. Depressive symptoms (HAM-D total endpoint, high = poor)</NAME>
<GROUP_LABEL_1>Antidepressant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="1.2400282374135538" CI_END="0.6973764138695908" CI_START="-3.0647362954416706" DF="2" EFFECT_SIZE="-1.1836799407860399" ESTIMABLE="YES" I2="0.0" ID="CMP-001.02.01" NO="1" P_CHI2="0.5379371553141743" P_Z="0.21745134100485541" STUDIES="3" TAU2="0.0" TOTAL_1="86" TOTAL_2="46" WEIGHT="73.42154994906619" Z="1.2333336252373281">
<NAME>non-skewed data</NAME>
<CONT_DATA CI_END="0.6266601121346707" CI_START="-4.286660112134671" EFFECT_SIZE="-1.83" ESTIMABLE="YES" MEAN_1="9.68" MEAN_2="11.51" ORDER="55" SD_1="4.41" SD_2="3.96" SE="1.2534210483011383" STUDY_ID="STD-Jasovic-1996" TOTAL_1="37" TOTAL_2="15" WEIGHT="43.046417458357965"/>
<CONT_DATA CI_END="4.013323142975613" CI_START="-3.0133231429756138" EFFECT_SIZE="0.5" ESTIMABLE="YES" MEAN_1="17.1" MEAN_2="16.6" ORDER="56" SD_1="4.9" SD_2="6.77" SE="1.792544746070978" STUDY_ID="STD-Kramer-1989" TOTAL_1="36" TOTAL_2="18" WEIGHT="21.04703721363264"/>
<CONT_DATA CI_END="3.2773645363981077" CI_START="-7.277364536398108" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="20.2" MEAN_2="22.2" ORDER="57" SD_1="8.0" SD_2="5.5" SE="2.692582403567252" STUDY_ID="STD-Mulholland-1997" TOTAL_1="13" TOTAL_2="13" WEIGHT="9.32809527707558"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.172438890719647" CI_END="-1.7314056192179712" CI_START="-7.984266282563338" DF="2" EFFECT_SIZE="-4.857835950890655" ESTIMABLE="YES" I2="75.52750131578061" ID="CMP-001.02.02" NO="2" P_CHI2="0.016802708263843336" P_Z="0.00232382759357757" STUDIES="3" TAU2="0.0" TOTAL_1="65" TOTAL_2="64" WEIGHT="26.578450050933824" Z="3.0453848307745934">
<NAME>skewed data</NAME>
<CONT_DATA CI_END="16.596254770861925" CI_START="-3.1962547708619287" EFFECT_SIZE="6.699999999999999" ESTIMABLE="YES" MEAN_1="22.7" MEAN_2="16.0" ORDER="58" SD_1="16.3" SD_2="13.9" SE="5.049202357248563" STUDY_ID="STD-Dufresne-1988" TOTAL_1="18" TOTAL_2="18" WEIGHT="2.6526834466296867"/>
<CONT_DATA CI_END="-3.9668839349531506" CI_START="-12.293116065046847" EFFECT_SIZE="-8.129999999999999" ESTIMABLE="YES" MEAN_1="13.2" MEAN_2="21.33" ORDER="59" SD_1="8.86" SD_2="7.54" SE="2.124077839126115" STUDY_ID="STD-Singh-1978" TOTAL_1="30" TOTAL_2="30" WEIGHT="14.989602772372457"/>
<CONT_DATA CI_END="2.5918527072752013" CI_START="-8.191852707275203" EFFECT_SIZE="-2.8000000000000007" ESTIMABLE="YES" MEAN_1="12.2" MEAN_2="15.0" ORDER="60" SD_1="8.3" SD_2="7.5" SE="2.750995809007435" STUDY_ID="STD-Siris-1987" TOTAL_1="17" TOTAL_2="16" WEIGHT="8.93616383193168"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="4.492891076615263" CI_START="-5.552891076615265" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5300000000000011" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.8361587425254247" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="28" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="0.20680936455946922">
<NAME>Mental state: 1b. Depressive symptoms (HAM-D total change, decline = good)</NAME>
<GROUP_LABEL_1>Antidepressant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.492891076615263" CI_START="-5.552891076615265" EFFECT_SIZE="-0.5300000000000011" ESTIMABLE="YES" MEAN_1="-8.73" MEAN_2="-8.2" ORDER="61" SD_1="8.53" SD_2="9.76" SE="2.5627466199558704" STUDY_ID="STD-Becker-1983" TOTAL_1="28" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="9.504559294251687" CI_END="4.307327807133802" CI_START="-3.1108033765172265" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="MD" EFFECT_SIZE="0.5982622153082878" ESTIMABLE="YES" I2="68.43620091028959" I2_Q="79.58277641302321" ID="CMP-001.04" NO="4" P_CHI2="0.02328298161211162" P_Q="0.02689066804831375" P_Z="0.7518986212475124" Q="4.897825582112223" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="97" TOTAL_2="79" UNITS="" WEIGHT="100.0" Z="0.31613687228924936">
<NAME>Mental state: 2a. General (BPRS total endpoint, high = poor)</NAME>
<GROUP_LABEL_1>Antidepressant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="4.606733712139461" CI_END="2.8656563014004233" CI_START="-5.176575432428261" DF="2" EFFECT_SIZE="-1.1554595655139188" ESTIMABLE="YES" I2="56.58529177126761" ID="CMP-001.04.01" NO="1" P_CHI2="0.09992201415542212" P_Z="0.5733043477620708" STUDIES="3" TAU2="0.0" TOTAL_1="79" TOTAL_2="61" WEIGHT="85.08163997291128" Z="0.5631917131841806">
<NAME>people whose condition was designated 'stable'</NAME>
<CONT_DATA CI_END="10.700936577946859" CI_START="-2.4409365779468546" EFFECT_SIZE="4.130000000000003" ESTIMABLE="YES" MEAN_1="45.13" MEAN_2="41.0" ORDER="62" SD_1="11.74" SD_2="11.55" SE="3.3525802666669215" STUDY_ID="STD-Kramer-1989" TOTAL_1="36" TOTAL_2="18" WEIGHT="31.862105859513232"/>
<CONT_DATA CI_END="5.087636494794324" CI_START="-9.487636494794323" EFFECT_SIZE="-2.1999999999999993" ESTIMABLE="YES" MEAN_1="26.6" MEAN_2="28.8" ORDER="63" SD_1="8.7" SD_2="10.2" SE="3.718250208819279" STUDY_ID="STD-Mulholland-1997" TOTAL_1="13" TOTAL_2="13" WEIGHT="25.903331472568578"/>
<CONT_DATA CI_END="0.7666657503424377" CI_START="-13.426665750342448" EFFECT_SIZE="-6.330000000000005" ESTIMABLE="YES" MEAN_1="43.8" MEAN_2="50.13" ORDER="64" SD_1="11.92" SD_2="15.85" SE="3.6208143651210105" STUDY_ID="STD-Singh-1978" TOTAL_1="30" TOTAL_2="30" WEIGHT="27.31620264082946"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="20.202934610552745" CI_START="0.9970653894472594" DF="0" EFFECT_SIZE="10.600000000000001" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="1.0" P_Z="0.030505390413348123" STUDIES="1" TAU2="0.0" TOTAL_1="18" TOTAL_2="18" WEIGHT="14.918360027088726" Z="2.163465552841949">
<NAME>people whose stability was not designated</NAME>
<CONT_DATA CI_END="20.202934610552745" CI_START="0.9970653894472594" EFFECT_SIZE="10.600000000000001" ESTIMABLE="YES" MEAN_1="42.5" MEAN_2="31.9" ORDER="65" SD_1="17.7" SD_2="10.9" SE="4.89954646427152" STUDY_ID="STD-Dufresne-1988" TOTAL_1="18" TOTAL_2="18" WEIGHT="14.918360027088726"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="9.87738661023315" CI_START="-4.037386610233149" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.920000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.41073970834089024" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="27" TOTAL_2="24" UNITS="" WEIGHT="100.0" Z="0.8225926135022088">
<NAME>Mental state: 2b. General (BPRS total change, decline = good)</NAME>
<GROUP_LABEL_1>Antidepressant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="9.87738661023315" CI_START="-4.037386610233149" EFFECT_SIZE="2.920000000000001" ESTIMABLE="YES" MEAN_1="-6.54" MEAN_2="-9.46" ORDER="66" SD_1="10.45" SD_2="14.33" SE="3.549752273568355" STUDY_ID="STD-Becker-1983" TOTAL_1="27" TOTAL_2="24" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.500253900547158" CI_END="0.24704606153464703" CI_START="-0.028864243352828847" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.10909090909090909" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="7" I2="86.66711803013698" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.60722206534228" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.9622114391106003" METHOD="MH" NO="6" P_CHI2="0.006169073190194219" P_Q="1.0" P_Z="0.12116976192155939" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="55" TOTAL_2="55" WEIGHT="100.0" Z="1.549882328216154">
<NAME>Adverse effects: 1. Any side effects</NAME>
<GROUP_LABEL_1>Antidepressant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="0.5232322937923578" CI_START="0.11676770620764218" EFFECT_SIZE="0.32" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="67" O_E="0.0" SE="0.10369185117452577" STUDY_ID="STD-Johnson-1981" TOTAL_1="25" TOTAL_2="25" VAR="0.010752000000000001" WEIGHT="45.45454545454545"/>
<DICH_DATA CI_END="0.12117505034352954" CI_START="-0.2545083836768629" EFFECT_SIZE="-0.06666666666666668" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="68" O_E="0.0" SE="0.09583937179043478" STUDY_ID="STD-Singh-1978" TOTAL_1="30" TOTAL_2="30" VAR="0.009185185185185185" WEIGHT="54.54545454545455"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="5" EVENTS_2="11" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="7" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="28" TOTAL_2="24" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 2. Extrapyramidal effects - clinically significant severity</NAME>
<GROUP_LABEL_1>Antidepressant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_DATA CI_END="-0.03509565627919739" CI_START="-0.5244281532446121" EFFECT_SIZE="-0.27976190476190477" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="69" O_E="0.0" SE="0.12483201243114848" STUDY_ID="STD-Becker-1983" TOTAL_1="28" TOTAL_2="24" VAR="0.01558303132761041" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.733652559928794" CI_END="0.08852239328191402" CI_START="-0.036297175846381764" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="RD" EFFECT_SIZE="0.026112608717766134" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="35" I2="14.775045972038862" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-1.0529468530471027" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5831497388573936" METHOD="MH" NO="8" P_CHI2="0.30327767150315177" P_Q="0.38912180792763584" P_Z="0.4121818684609676" Q="0.7416845899346195" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="245" TOTAL_2="221" WEIGHT="200.0" Z="0.8200600753012236">
<NAME>Leaving the study early</NAME>
<GROUP_LABEL_1>Antidepressant</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1/>
<GRAPH_LABEL_2/>
<DICH_SUBGROUP CHI2="12.205685807435614" CI_END="0.09986593884179445" CI_START="-0.02352155321905832" DF="9" EFFECT_SIZE="0.03817219281136807" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="24" I2="26.26387290325574" ID="CMP-001.08.01" LOG_CI_END="-1.0005826108271898" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.418252891176833" NO="1" P_CHI2="0.20196062996247122" P_Z="0.22524383502276435" STUDIES="10" TAU2="0.0" TOTAL_1="225" TOTAL_2="201" WEIGHT="100.0" Z="1.212701901490988">
<NAME>before 12 weeks</NAME>
<DICH_DATA CI_END="0.13322788631979665" CI_START="-0.06179931489122524" EFFECT_SIZE="0.03571428571428571" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="70" O_E="0.0" SE="0.049752751262107764" STUDY_ID="STD-Becker-1983" TOTAL_1="28" TOTAL_2="24" VAR="0.0024753362581491655" WEIGHT="12.357759821677346"/>
<DICH_DATA CI_END="0.6464290138202766" CI_START="0.09041309144288123" EFFECT_SIZE="0.3684210526315789" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="71" O_E="0.0" SE="0.14184340293066047" STUDY_ID="STD-Dufresne-1988" TOTAL_1="19" TOTAL_2="19" VAR="0.020119550954949703" WEIGHT="9.084424630816383"/>
<DICH_DATA CI_END="0.11051766347027074" CI_START="-0.11051766347027074" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="72" O_E="0.0" SE="0.05638759913040237" STUDY_ID="STD-Hogarty-1995" TOTAL_1="16" TOTAL_2="17" VAR="0.0031795613356909542" WEIGHT="7.881861242685984"/>
<DICH_DATA CI_END="0.0746548727053014" CI_START="-0.0746548727053014" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="73" O_E="0.0" SE="0.038089920679241815" STUDY_ID="STD-Johnson-1981" TOTAL_1="25" TOTAL_2="25" VAR="0.0014508420573509332" WEIGHT="11.953190303705767"/>
<DICH_DATA CI_END="0.19739036382776928" CI_START="-0.19739036382776928" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="74" O_E="0.0" SE="0.10071121989218132" STUDY_ID="STD-Kramer-1989" TOTAL_1="44" TOTAL_2="22" VAR="0.010142749812171298" WEIGHT="14.025076623014765"/>
<DICH_DATA CI_END="0.3039680974836545" CI_START="-0.3039680974836545" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="75" O_E="0.0" SE="0.15508861381194555" STUDY_ID="STD-Kurland-1981" TOTAL_1="14" TOTAL_2="14" VAR="0.024052478134110787" WEIGHT="6.69378657007523"/>
<DICH_DATA CI_END="0.5231470520273316" CI_START="-0.21545474433502387" EFFECT_SIZE="0.15384615384615385" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="76" O_E="0.0" SE="0.1884222879063983" STUDY_ID="STD-Mulholland-1997" TOTAL_1="13" TOTAL_2="13" VAR="0.03550295857988166" WEIGHT="6.2156589579269985"/>
<DICH_DATA CI_END="0.09724325539188422" CI_START="-0.49724325539188424" EFFECT_SIZE="-0.2" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="77" O_E="0.0" SE="0.15165750888103102" STUDY_ID="STD-Prusoff-1979" TOTAL_1="20" TOTAL_2="20" VAR="0.023" WEIGHT="9.562552242964614"/>
<DICH_DATA CI_END="0.0627126957943536" CI_START="-0.0627126957943536" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="78" O_E="0.0" SE="0.03199686131430135" STUDY_ID="STD-Singh-1978" TOTAL_1="30" TOTAL_2="30" VAR="0.0010237991339666342" WEIGHT="14.34382836444692"/>
<DICH_DATA CI_END="0.3096815189458224" CI_START="-0.05968151894582238" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="79" O_E="0.0" SE="0.094226996211444" STUDY_ID="STD-Siris-1987" TOTAL_1="16" TOTAL_2="17" VAR="0.00887872681503148" WEIGHT="7.881861242685984"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.781535128837316E-33" CI_END="0.2083441353620652" CI_START="-0.40834413536206526" DF="0" EFFECT_SIZE="-0.10000000000000005" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" I2="100.0" ID="CMP-001.08.02" LOG_CI_END="-0.681218719904281" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" NO="2" P_CHI2="0.0" P_Z="0.5250099701563306" STUDIES="1" TAU2="0.0" TOTAL_1="20" TOTAL_2="20" WEIGHT="100.0" Z="0.6356417261637286">
<NAME>12 weeks or more</NAME>
<DICH_DATA CI_END="0.2083441353620652" CI_START="-0.40834413536206526" EFFECT_SIZE="-0.10000000000000003" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="80" O_E="0.0" SE="0.15732132722552272" STUDY_ID="STD-Prusoff-1979" TOTAL_1="20" TOTAL_2="20" VAR="0.02475" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>